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ABSTRACT
5-HT4 receptors are expressed in colonic epithelium, and activation with 5-HT4
receptor agonists causes a number of responses, including mucus secretion from goblet
cells, chloride secretion from enterocytes, and 5-HT release from enterochromaffin cells.
We tested whether this receptor could serve a protective role in models of colitis and
under basal conditions.
Male CD-1 mice (Charles River, Canada) were administered dextran sodium sulfate
(DSS; 4% w/v in tap water, MW: 40,000) or trinitrobenzene sulfonic acid (TNBS;
7.5mg/mL in 50% ethanol by enema) on day 0. Treatment with the 5-HT4 receptor
agonist, tegaserod (1 mg/Kg), or agonist plus the antagonist, GR113808 (1 mg/Kg),
began either 24 hours after colitis induction and continued daily for 6 days (prevention
paradigm), or 5 days after colitis was induced and continued for 10 days (recovery
paradigm). To test for an action of 5-HT4 receptors under basal conditions, the
antagonist, GR113808 was administered to normal mice by daily enema for 10 days.
Colitis was evaluated using disease activity index (DAI) and histological damage scores
(HDS). Possible protective mechanisms such as improved epithelial barrier function
were evaluated by cell proliferation by Ki-67 immunostaining, whereas cell migration
and resistance to oxidative stress were explored in CaCo-2 cells. We also tested the
effects of tegaserod and/or GR113808 on colonic motility in guinea pigs, a well described
model of colonic function.
Treatment with tegaserod by enema in both DSS and TNBS-inflamed animals
significantly attenuated the development of colitis, and accelerated recovery from
established colitis, and these effects were blocked by 5-HT4 antagonist treatment. This
effect was not seen when tegaserod was administered by intraperitoneal injection.
TNBS-induced dysmotility in guinea pigs was significantly reversed by 5-HT4 receptor
agonist treatment, but dysmotility persisted in animals treated with the agonist plus
antagonist. We observed significant increases in the proportion of epithelial cells that
were Ki-67 positive in DSS-inflamed mice treated with the agonist, and this effect was
blocked by the antagonist. In CaCo-2 cells, 5-HT4 receptor activation accelerated cell
migration into scratches on cell cultures, and increased resistance to oxidative stressinduced apoptosis, and these effects were blocked by the antagonist. Furthermore,
treatment with the antagonist alone resulted in significant increases in disease activity
index, histological damage scores and bacterial translocation in mice, and led to disrupted
motility patterns in guinea pig distal colon. 5-HT4 receptor stimulation reduced the
development of, and accelerated the recovery from, inflammation. These effects likely
involved improved wound healing and resistance to oxidative stress. Interestingly,
inhibition of 5-HT4 activity in normal animals resulted in inflammation, decreased
epithelial proliferation and disrupted motility.
Taken together, these data suggest that activation of mucosal 5-HT4 receptors has a
protective effect in the normal and the inflamed colon.
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CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
I. Structure of the Gastrointestinal Tract
A. Organization and Function
The gastrointestinal (GI) tract consists of several organs that are continuous with one
another. The purpose of the GI tract is to digest food so that the body can absorb the
calories and nutrients from it. The GI tract starts in the mouth, or the oral cavity, where
muscles of mastication and the tongue help to mix saliva and food to start the digestion
process. After chewing and swallowing, the contents move down the esophagus through
the actions of peristalsis. To pass from the esophagus to the stomach, the contents must
pass through the lower esophageal sphincter. Once in the stomach, hydrochloric acid is
secreted into the lumen and the muscles of the stomach churn the contents to help further
mix and digest. The stomach continues to churn and mix as fractions of the contents are
passed on to the proximal part of the small intestine through the pyloric sphincter.
The small intestine is made up of three continuous regions, from proximal to distal;
the duodenum, jejunum, and ileum. Due to their continuous nature, there are not distinct
gross landmarks to differentiate the start of these regions, but they do contribute to
digestion in different ways. The duodenum, which is most proximal, is shortest, widest
and most fixed to the body wall. It is also the site where the bile duct and pancreatic duct
merge to connect to the duodenum through the sphincter of Oddi. It is here, in the
duodenum, where fats begin to emulsify, proteins are chopped into useable pieces and
digestion is nearly finished. The duodenum gives way to the jejunum at the
duodenojejunal junction. The jejunum is longer than the duodenum and has a thinner
wall. The jejunum is important for absorbing proteins and carbohydrates into the body.
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There is no distinct point where the jejunum becomes the ileum, but rather a transition
from one set of characteristics to another. The wall of the small intestine becomes
thinner as it becomes the ileum, there are fewer circular folds in the tissue, and there is an
increase in the number of arterial arcades. The ileum is important for absorbing vitamin
B12 and reabsorbing bile salts. The small intestine meets the large intestine at the
ileocecal junction.
The large intestine, or colon, is grossly different from the small intestine in a number
of ways. The large intestine has three thick longitudinal bands of muscle called taenia
coli and the spaces between are called haustra. In the human large intestine, the segments
are named for their location or direction: ascending colon, transverse colon, descending
colon, and sigmoid colon, followed by the rectum. In rodent and guinea pigs, the colon is
simply divided into proximal colon, which is nearer the cecum, and distal colon, nearer
the rectum. The function of the colon is to maintain a water balance, secreting and
absorbing water to the lumen for the formation of pliable feces, and storage.
B. Tissues of the Gastrointestinal Tract
There are four layers to the GI tract: the mucosa, submucosa, muscularis externa and
serosa, demonstrated in Figure 1. The mucosa is the innermost layer and is adjacent to
the lumen. The submucosa is between the mucosa and the muscularis externa. The
muscularis externa is comprised of two perpendicular layers of smooth muscle. The
serosa is a thin membranous tissue that covers all abdominal organs and is a continuation
of the peritoneal membrane.
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Figure 1
Schematic diagram of the layers of the gut depicting location and general features.
(image source: "2402 Layers of the Gastrointestinal Tract" by OpenStax College, Rice
University. Licensed under CC BY 3.0 via Wikimedia Commons https://commons.wikimedia.org/wiki/File:2402_Layers_of_the_Gastrointestinal_Tract.jp
g#/media/File:2402_Layers_of_the_Gastrointestinal_Tract.jpg)
1. Mucosa
The mucosa is made up of a single layer of simple columnar epithelial cells, the
lamina propria and a thin layer of smooth muscle called the muscularis mucosae. The
epithelium is arranged into crypts and villi in the small intestine and just crypts in the
large intestine. The epithelial cells are incredibly varied and include transporting cells
(also known as enterocytes), endocrine cells, exocrine secretory cells, and stem cells
(Wright, 2012). Transporting cells serve secretory and absorptive functions, moving
nutrients, water, and ions between the lumen and the interstitial space of the lamina
propria. Secretory cells have different effectors based on their cellular location. At the
apical surface, secretory cells release enzymes, mucus, and paracrine signaling molecules
3

into the lumen. At the basal side, secretory cells release compounds that can enter the
circulation and act as hormones into the blood vessels, and they can act locally as
paracrine signaling molecules by stimulating receptors on nearby cells and nerve fibers.
The lamina propria of the mucosal layer is a subepithelial connective tissue layer that
is rich in small nerve fibers, blood vessels, and lymphatic vessels. Also in this layer are
immune cells that detect and attack pathogens that may enter via breaches in the mucosal
barrier (Berkes et al., 2003).
The outermost layer of the mucosa is the muscularis mucosae. This thin layer of
smooth muscle separates the mucosa from the submucosa. Functionally, it is thought that
this muscle acts to move the villi of the small intestine to increase surface area for
absorption (Poole and Furness, 2012).
2. Submucosa
The submucosa is a connective tissue layer between the mucosa and the muscularis
externa. In the submucosal space there are blood vessels, lymph nodes, and the
submucosal (Meissner’s) plexus, which will be described later.
3. Muscularis Externa
The muscularis externa consists of two layers of smooth muscle, an inner circular
layer, and an outer longitudinal layer. The inner smooth muscle layer is oriented in
circular rings that contract to make the lumen of the gut tube smaller. The outer smooth
muscle layer is oriented longitudinally and contracts to shorten the length of the gut tube.
It is the coordinated contractions of these muscles that result in the motility patterns that
mix the luminal contents during the digestive period, and propel the contents in the aboral
direction. These motility patterns are referred to as segmentation and peristalsis,
4

respectively. Between the two smooth muscle layers is the myenteric (Auerbach’s)
plexus, which generates and coordinates the contractions resulting in the motility patterns
described above.
4. Serosa
Serosa is a continuation of the peritoneal membrane. It lines the abdominal cavity and
forms mesentery, which holds the intestines in place to prevent tangling as they contract
and move. This layer also secretes fluid to lubricate the organs as they move during
digestion.
II. Enteric Nervous System Cells
The enteric nervous system (ENS) was originally described by Langley as one of the
three divisions of the autonomic nervous system, differing from the parasympathetic and
sympathetic branches in that it does not require central nervous system input (Langley,
1921). There are two main neuronal networks in the ENS, the submucosal plexus and the
myenteric plexus (Furness and Costa, 1980). The neurons and glia of the ENS are
derived from the neural crest. Throughout most of the gut, the ganglia are formed by
vagal neural crest cells, but sacral crest cells colonize the gut in the distal colon and
rectum (Lake and Heuckeroth, 2013). The ENS can modulate motor function, blood
flow, mucosal transport and secretion, as well as endocrine functions in the GI tract.
A. Enteric Nervous System Cell Types
1. Sensory Neurons
Sensory neurons play a critical role in the ENS. Neurons can be named for the type
of energy or stimulus they respond to: heat (thermo), movement or stretch (mechano) or
chemical (chemo). Extrinsic sensory afferent fibers with cells bodies in the nodose or
5

dorsal root ganglia communicate information on satiety and nociception from the GI tract
to the central nervous system (CNS) (Vermeulen et al., 2014). There are also intrinsic
primary afferent neurons (IPANs), which can sense and respond to stimuli in the GI tract
without the involvement of the CNS (Furness et al., 2013). These IPANs are considered
primary afferent because they continue to function in the presence of synaptic blockers,
indicating that they are not downstream from another neuron, and because they are
uniquely positioned within the GI tract (intrinsically) to receive luminal and mucosal
information. Since IPANs do not directly project into the lumen, they receive paracrine
signals in the form of chemical mediators such as serotonin and ATP released from
enteroendocrine cells.
2. Motor Neurons
Motor neurons are either excitatory or inhibitory, and in the ENS they originate in the
myenteric plexus and have overlapping regions of control. Excitatory transmission is
primarily through acetylcholine (ACh) and substance P, with separate sets of neurons
targeting the longitudinal and circular smooth muscle (Bornstein et al., 2004). Inhibitory
neurons project directly to the circular smooth muscle and transmit their signals to the
longitudinal muscle from small fiber bundles in the plane of the myenteric plexus that are
collectively called the tertiary plexus. Inhibitory motor neurons use nitric oxide (NO) and
purines as their primary neurotransmitters (Bornstein et al., 2004).
Additional types of motor neurons exist within the ENS. Secretomotor neurons
function to cause gastric secretion such as acid and pepsin in the stomach, as well as
mucus and other molecules from enteroendocrine cells in the small and large intestines.

6

Secretomotor neurons in the submucosal plexus cause fluid secretion all along the
intestine (Costa et al., 2000).
3. Interneurons
Interneurons are essential for the proper function of the ENS. Sensory neurons
synapse onto ascending and descending interneurons, which then signal through ACh
release to upstream excitatory motor neurons or downstream to inhibitory motor neurons
(Costa et al., 1996).
4. Enteric Glia
Like the CNS, the ENS contains glia. Enteric glial cells express both S-100β and
glial fibrillary acidic protein (GFAP), similar to astrocytes of the CNS (Neunlist et al.,
2014). Enteric glial cells wrap around enteric neurons and interganglionic fibers where
they can modulate neuronal signaling, as well as protect and support the neurons.
Furthermore, enteric glia can act as a bridge between enteric nerves, endocrine cells,
immune cells and epithelial cells, facilitating connectivity and improving intercellular
communication (Neunlist et al., 2013; Sharkey, 2015). There is also evidence that enteric
glial cells can act as progenitor cells for both glia and neurons (Neunlist et al., 2014).
B. Submucosal Plexus
The submucosal plexus (Meissner’s) is found primarily in the small and large
intestine in the submucosal space. This network responds to mechanical stimulation of
the mucosa or distension. Cells in these ganglia provide the secretomotor innervation to
the intestinal villi and crypts as well as vasodilatory input to blood vessels in the region.
These neurons also send and receive projections from the myenteric plexus, thus
integrating the ENS.
7

C. Myenteric Plexus
The myenteric plexus (Auerbach’s) is a continuous network of ganglia that extends
from the esophagus to the internal anal sphincter. It is located between the layers of
smooth muscle in the muscularis externa. The neurons of this plexus are arranged in a
monolayer rather than in 3-dimensional clusters. The motor neurons responsible for
regulation of the circular and longitudinal smooth muscles are found in this plexus. The
ascending limbs of the peristaltic circuit, including interneurons and excitatory motor
neurons, project upstream causing contraction oral to the site of stimulation, whereas the
interneurons and motor neurons of the descending limb that cause relaxation, project
aborally. The combination of increased pressure above, and decreased pressure below,
causes movement of luminal contents along the intestines.
D. Enteric Circuitry
The circuitry of the ENS is critical for motor control, glandular secretions, movement
of fluid, and local blood flow (Furness, 2012). These components work in concert to
produce specialized digestive patterns such as the mixing of luminal content or the
migrating motor complex. Like most integrated circuits, enteric circuits consist of
sensory neurons, interneurons, and motor neurons. Sensory neurons synapse onto
interneurons in both enteric ganglia. Interneurons connect with sensory neurons, motor
neurons and other interneurons to form extensive networks that integrate the sensory
information into a coherent message that motor neurons respond to (Costa et al., 2000).
These interneuron circuits can be logical integrative circuits that take the sensory
information and create a motor output that is not the same signal as the input, or reflex
circuits, which are stereotyped responses to a stimulus. While the ENS circuitry can
8

operate without CNS input, signals from the CNS can override the intrinsic activity of the
ENS.
III. Serotonin
Serotonin (enteramine, 5-hydroxytryptamine, 5-HT) is a major signaling molecule for
both the brain and the gut, acting as both a neurotransmitter and a paracrine signaling
molecule. It is synthesized in neurons and non-neuronal cells by the rate-limiting
enzymes tryptophan hydroxylase 1 (TpH1) and TpH2. In physiological conditions
serotonin is basic, carries a positive charge and cannot readily cross a lipid membrane,
therefore it must be actively transported into cells by the serotonin reuptake transporter
(SERT) where it is degraded by monoamine oxidase A (MAO-A). In the human body,
over 90% of the serotonin is produced and acts in the GI tract, and fortunately, the
serotonin produced there cannot directly influence the brain because serotonin cannot
cross the blood brain barrier (Mawe and Hoffman, 2013).
A. History
Serotonin was initially discovered by Vittorio Erspamer in 1937, who isolated the
amine which he called “enteramine” from the gastrointestinal tracts of vertebrates
(Erspamer, 1937) and later described it as the major storage or secretion product of
enterochromaffin (EC) cells (Erspamer and Asero, 1952). In 1948, Page and Rapport
described an isolated molecule from bovine serum that acted as a vasoconstrictor, which
they named “serotonin” (Rapport et al., 1948). It was subsequently demonstrated that
serotonin and enteramine were indeed the same molecule, acting on different systems
(Hamlin and Fischer, 1951; Erspamer and Asero, 1952). In the late 1950s, Edith
Bulbring described the release of local 5-HT due to increased intraluminal pressure and
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the peristaltic reflex in isolated guinea pig preparations (Bulbring and Lin, 1958;
Bulbring and Crema, 1959). She noted that application of 5-HT to different tissue sites
elicited different responses, namely, 5-HT in the lumen facilitated the peristaltic reflex
but serosal application abolished the peristaltic reflex, and that this inhibition could be
overcome by luminal application of 5-HT (Bulbring and Crema, 1958).
While we now know that 5-HT is both a gut signaling molecule, as well as a gut and
brain neurotransmitter, it was only in the last 20 years that we came to understand its
synthesis by the rate-limiting enzyme tryptophan hydroxylase (TpH) (Yu et al., 1999),
and only in the last 12 years that we have appreciated that different isoforms of this
enzyme contribute to different 5-HT populations (Walther and Bader, 2003; Walther et
al., 2003). TpH1 is the isoform responsible for non-neuronal 5-HT (Walther and Bader,
2003) and TpH2 is responsible for neuronal 5-HT (Walther et al., 2003).
1. Neuronal signaling
There are two sources of 5-HT in the gut; the ENS includes serotonergic neurons that
use TpH2, like brain neurons, to synthesize 5-HT (Walther et al., 2003). While there are
many neurons in the ENS, only about 1-2% of them are serotonergic, and they are located
in the myenteric ganglia (Costa et al., 1996). These serotonergic myenteric neurons
project downstream and preferentially synapse on other serotonergic neurons to create a
descending network of interneurons that travels along the gut tube (Furness and Costa,
1982; Young and Furness, 1995). One of the roles of this circuit could be to send signals
to different areas of the bowel. An example of this is the gastro-colic reflex, which is
intrinsic to the gut, and is suppressed by antagonists of the 5-HT3 receptor (Liu et al.,

10

2011). The 5-HT4 receptor mediates the serotonergic fast excitatory postsynaptic
potential in the ENS (Galligan et al., 2003).
2. Mucosal Signaling
Serotonin is stored in secretory vesicles in EC cells and is released into the lamina
propria (Bulbring and Crema, 1959; Bertrand, 2004; Patel et al., 2007; Raghupathi et al.,
2013) in a calcium-dependent manner (Racke et al., 1996) that can be modulated by ATP
or other purines (Linan-Rico et al., 2013). Erspamer and Bulbring commented on the
role of EC cells as a “diffuse endocrine organ” (Erspamer, 1966) and “transducers”
(Bulbring and Crema, 1959), respectively, and indeed, EC cells respond to mechanical
and chemical stimulation from the lumen. The secreted 5-HT acts on sensory fibers
containing 5-HT receptors in the lamina propria that initiate a variety of physiological
responses such as digestive reflexes, satiety, visceral sensation, secretion, and
vasodilation. Although we often think of 5-HT’s actions in the lamina propria, it has
been shown that some 5-HT leaks or is even transported into the lumen (Fujimiya et al.,
1997).
3. Serotonin Reuptake Transporter
Due to the many functions of 5-HT, its actions must be rapidly terminated by removal
from the interstitial space. The main mechanism of removing 5-HT from the lamina
propria is by the high affinity selective serotonin reuptake transporter (SERT) (Wade et
al., 1996), which is expressed on cells in the epithelium, on platelets, and myenteric
neurons (Wade et al., 1996; Chen et al., 2001). There is no specific extracellular
degradation enzyme for 5-HT. When it is taken up into cells that express SERT, 5-HT is
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broken down to form its main metabolite, 5-hydroxyindoleacetic acid (5-HIAA), by the
mitochondrial enzyme, monoamine oxidase-A.
4. Serotonin Signaling in Pathophysiology
Serotonin also plays a role in inflammation. Animal models of GI inflammation,
such as the trinitrobenzene sulfonic acid (TNBS) guinea pig model of colitis, demonstrate
that there are changes in serotonin signaling such as increased colonic 5-HT content,
increased EC cell number, increased 5-HT release from EC cells, and reduced expression
of SERT (Linden et al., 2003b; Linden et al., 2005). Additionally, in mice lacking SERT,
TNBS colitis is worse than in wild-type, contributing evidence that increased
bioavailability of 5-HT is proinflammatory (Bischoff et al., 2009). Furthermore, we can
attribute the increase in 5-HT to mucosal 5-HT because TpH1 knockouts, which are
incapable of making mucosal 5-HT, show a delay to disease onset when given dextran
sodium sulfate (DSS) or DNBS-induced colitis (Ghia et al., 2009). In studies conducted
on mucosal biopsies from inflammatory bowel disease patients, there is a measured
decrease in SERT expression (Mawe and Hoffman, 2013). Collectively, there is a large
body of evidence that demonstrates a role for 5-HT in inflammation.
B. Serotonin Receptors
There are seven families of 5-HT receptors, with a combined total of at least 14
subtypes (Hoyer et al., 2002; Daubert and Condron, 2010). The families are named 5HT1 through 5-HT7 and are G-protein coupled receptors, except for 5-HT3 which is a
ligand-gated ion channel. In the GI tract and the ENS, five of these families of 5-HT
receptors are expressed (5-HT1, 5-HT2, 5-HT3, 5-HT4, and 5-HT7). The most extensively
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studied 5-HT receptors in the gut are the 5-HT3 and 5-HT4 receptors. Figure 2 shows the
known locations and roles of those GI 5-HT receptors.

Figure 2
Schematic diagram demonstrating the currently known locations of 5-HT receptors in the
gut. Notably, 5-HT4 receptors (red) are expressed on nerve terminals as well as
enterochromaffin cells, enterocytes and goblet cells. “+” indicates excitation and “-“
indicates inhibiton (Figure taken from Mawe and Hoffman, 2013)
1. 5-HT4 Receptors
As mentioned, the 5-HT4 receptor is a seven transmembrane spanning G-protein
coupled receptor and is positively coupled to adenylate cyclase (Hegde and Eglen, 1996;
Hoyer et al., 2002; Nichols and Nichols, 2008). The 5-HT4, along with the 5-HT3, is one
of the most extensively studied 5-HT receptors in the periphery and the two receptors
have been common targets for pharmacotherapies to treat IBS (De Maeyer et al., 2008).
5-HT4 receptor agonists had been used to treat constipation-predominate IBS because it
acts as a prokinetic agent. Due to real and/or potential cardiovascular side effects, both
13

tegaserod and cisapride, 5-HT4 receptor agonists, were removed from the market,
however prucalopride is still available in some countries, but not yet in the USA.
The 5-HT4 receptor is expressed in a variety of systems, including the limbic system,
heart, urinary bladder and the GI tract. In the ENS, 5-HT4 receptors are located on nerve
terminals and they facilitate acetylcholine release and enhance myogenic tone (Galligan
et al., 2003; Leclere et al., 2005). It was recently shown that 5-HT4 receptors are also
expressed on a number of epithelial cell types in the GI tract (Hoffman et al., 2012).
Using a variety of techniques from visualizing fluorescence in 5-HT4-eGFP-BACtransgenic mice combined with immunohistochemistry to running RT-PCR on RNA
extracted from mucosal scrapings of animal models and human intestines, it was
demonstrated that 5-HT4 receptors are expressed on cells in the epithelium such as
enteroendocrine cells, EC cells, and goblet cells (Hoffman et al., 2012). Stimulation of
these receptors causes chloride (Cl-) ion movement, mucus secretion, and 5-HT release
(Hoffman et al., 2012). Relevant to IBS and IBD, activation of 5-HT4 receptors also
increases colonic propulsive motility and reduces visceral hypersensitivity in animal
models (Greenwood-Van Meerveld et al., 2006; Hoffman et al., 2012; Yu et al., 2015).
2. Agonists and Antagonists of 5-HT4
Agonists of the 5-HT4 receptor may also influence GI motility through activation of
efferent myenteric neurons causing a release of acetylcholine (ACh) and enhancing
smooth muscle contraction and they are considered a prokinetic drug (De Maeyer et al.,
2008). Non-muscular effects of activation via agonists of 5-HT4 also include increased
secretions of Cl- (De Maeyer et al., 2008; Hoffman et al., 2012).
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A unique feature of 5-HT4 receptors is their ability to be activated by a varied group
of chemical classes with a variety of effects, as illustrated in Table 1 (De Maeyer et al.,
2008). The first class of prokinetic used was metoclopramide, which targeted both 5-HT4
and 5-HT3 receptors as well as the dopamine 2 (D2) receptor. From this class of drugs,
ligands that did not target dopamine receptors were created, such as cisapride (De Maeyer
et al., 2008). Drugs such as tegaserod were also designed off the backbone of the
serotonin molecule. A new class of drugs has emerged, the
dihydrobenzofurancarboxamides, like prucalopride (De Maeyer et al., 2008).
Drug
Serotonin

5-HT4
+

5-HT3
+

Metoclopramide

+

-

Others
All 5-HT
receptors
- for D2

Renzapride

+

-

- for D2

Cisapride

+

-

- for 5-HT2

Prucalopride
Tegaserod

+
+

+for 5-HT1
- for 5-HT2

Uses

Anti-emetic,
slows gastric
emptying
Anti-emetic,
Slows colonic
transit,
Increased fluid
absorption
Dyspepsia,
gastroparesis,
Pseudoobstruction
Hypomotility
IBS with
constipation

Table 1. Selected 5-HT4 Receptor Agonist Features
As illustrated in Table 1, many of the compounds used for their effects on the 5-HT4
receptor have other targets as well. There are some benefits and pitfalls to this lack of
selectivity. In the case of drugs that have their effect on 5-HT3, 5-HT4 and D2 receptors,
the anti-emetic and slowed gastric empyting properties are what made it very popular;
however, antagonism of the D2 receptor also caused pituitary gland release of prolactin
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(Parra et al., 1997). Drugs that employ agonistic effects at 5-HT4 receptors and
antagonist effects at 5-HT3 receptors could have conflicting effects, as agonism of 5-HT4
receptors should have a prokinetic effect while antagonism of 5-HT3 should slow
motility. Although it seems like this would be a problem, it could be resolved by spatial
organization of the 5-HT3 and 5-HT4 receptors such that patients treated with cisapride
showed an increase in upper GI transit time but little prokinetic effect on colonic motility
(De Maeyer et al., 2008). Furthermore, cisapride and tegaserod have very different
absorption rates; cisapride is readily absorbed and could act on the upper GI tract where
there are fewer 5-HT4 receptors, while tegaserod is not readily absorbed and could
theoretically remain unused until it reached the colon where there are more 5-HT4
receptors (Hoffman et al., 2012). Tegaserod is a non-specific, partial 5-HT4 agonist and
thus, has other low affinity targets that include 5-HT1 and 5-HT2 receptors, serotonin
reuptake transporter, dopamine active transporter, and noradrenaline transporter (De
Maeyer et al., 2008).
GR113808 and SB204070 are selective 5-HT4 antagonists commonly used
experimentally. Applications of these antagonists have been shown to block the TTXinsensitive release of 5-HT that is activated by 5-HT4 agonists (Hoffman et al., 2012);
thus, antagonists of 5-HT4 receptors reduce the release of serotonin. It was also shown
that in the presence of both an agonist and antagonist (delivered orally or intracolonic),
the reduction in visceral hypersensitivity was blocked (Greenwood-Van Meerveld et al.,
2006; Hoffman et al., 2012) suggesting that agonist effects of the activation of 5-HT4
receptors reduces visceral hypersensitivity. In cell lines, 5-HT4 agonist treatment
stimulates neuronal outgrowth and is important for neuronal survival, while 5-HT4
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antagonists reduced the number of neurons and the length of their processes in culture,
thus blocking 5HT4 receptors probable neuroprotective role (Gershon and Liu, 2007).
Although 5-HT4 antagonists are not frequently used in treatment of Irritable Bowel
Syndrome (IBS), many 5-HT3 antagonists are used. Pharmaceuticals such as ondansetron
and granisetron are 5-HT3 antagonists frequently prescribed to alleviate the nausea and
discomfort associated with cancer chemotherapy drugs or for the relief of diarrhea
predominant IBS (Gershon and Tack, 2007; Mawe and Hoffman, 2013).
C. Nonconventional actions of serotonin
1. Microbiota
An increasingly recognized contributor to gut function is the microbiota, or the
bacteria in the gut. Less than ten years ago, our understanding of microbial impact on GI
function was merely correlations confounded by the differences in populations, the huge
number of gut bugs, and the dynamic nature of gut microenvironments (Khor et al.,
2011). It is known that dietary nutrients influence gut function, both directly on the ENS
and indirectly via receptor stimulation on enteroendocrine cells (Neunlist and Schemann,
2014). In fact, the gut microenvironment is a dynamic interplay between mucus, which
contains glycans, polysaccharides and dietary nutrients from the host, and the microbiota
that reside in the lumen (Pelaseyed et al., 2014).
An elegant set of experiments recently demonstrated that indigenous gut microbiota
upregulates the TpH1 activity of EC cells to increase 5-HT levels both in the colon and in
the blood, resulting in increased myenteric stimulation and thus gut motility (Yano et al.,
2015). Importantly, it was demonstrated that the modulation of 5-HT through gut
microbiota was inducible and reversible, showing that modulation can occur at any point
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and may be a therapeutic approach. Another group showed that luminally applied short
chain fatty acids (SCFAs) such as acetate and butyrate, which are made by human gut
microbes that ferment dietary saccharides, increases TpH1 mRNA expression and EC cell
produced 5-HT (Reigstad et al., 2015). To further demonstrate this, germ free mice were
colonized with human gut microbiota and 5-HT parameters were evaluated. They saw
that humanized germ free mice had increased TpH1 expression with no change in EC cell
number or SERT, suggesting that the microbiota influence EC cell function through
SCFAs (Reigstad et al., 2015). Functionally, in isolated guinea pig colon, it has been
shown that luminal treatment with SCFAs can alter gut motility, such that butyrate
increases full propagating contractions in the proximal colon and propionate inhibits full
propagating waves (Hurst et al., 2014). Together, these findings suggest that human gut
microbes that produce SCFAs may be an alternative approach to altering 5-HT
availability and net functional motility in the gut.
2. Obesity
Another hot topic is the role of 5-HT in obesity and energy metabolism. Globally,
obesity has risen dramatically in the last few decades, and many approaches have been
used to combat it. An initial report showed that the precursor to 5-HT, tryptophan, was
reduced in obese humans, and weight loss did not restore circulating 5-HT levels (Breum
et al., 2003). Subsequently, it was shown that liver and serum metabolites, including 5HT, were increased in obese mice (Kim et al., 2011). In rats fed a western diet, there was
increased body weight, glucose, and increased peak 5-HT release from intestinal EC cells
and increased steady state 5-HT levels with a decrease in SERT function (Bertrand et al.,
2011). These were interesting findings because it is known that 5-HT is involved in
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appetite regulation via the CNS, but serum 5-HT content is not indicative of CNS 5-HT,
so it is important to examine how circulating 5-HT might be modulating energy
metabolism and obesity.
It is also known that 5-HT colocalizes with insulin in granules in pancreatic β cells,
and it was shown that intracellular 5-HT regulates insulin and is critical for the regulation
of pancreatic β cell proliferation during pregnancy (Paulmann et al., 2009; Kim et al.,
2010). Blocking gut derived 5-HT in pregnant mice, either by reducing tryptophan in the
diet or by using TpH1 inhbitors, can induce glucose intolerance. Furthermore, it was
shown that 5-HT2B receptors on the maternal islet cells of the pancreas were responsible
for this change; inhibiting 5-HT2B receptors resulted in glucose intolerance as well. It
was also shown that certain variants of TpH1 and 5-HT2B receptors are associated with
measures of obesity such as waist circumference and BMI (Kwak et al., 2012). In a study
examining how gut derived 5-HT more directly determines metabolism in the nonpregnant state, it was shown that 5-HT from the gut acts through 5-HT2B receptors on
adipocytes to favor lipolysis and hepatocytes to encourage gluconeogenesis in mice
(Sumara et al., 2012). The net effect of 5-HT2B receptor activation is to maintain blood
glucose levels, which is typically beneficial when fasting. Furthermore, in a diet induced
animal model of type 2 diabetes it was shown that inhibiting TpH1, and thus gut 5-HT,
improves glucose tolerance (Sumara et al., 2012). Recent reports also show that TpH1
knockouts fed a high fat diet were protected from weight gain and the related metabolic
changes such as insulin resistance and nonalcoholic fatty liver disease, likely through
increased brown adipose tissue thermogenesis by suppressing β-adrenergic induced
expression of Upc1 (mitochondrial uncoupling protein 1) (Crane et al., 2015).
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3. Blood
Aside from the many roles 5-HT plays in the gut, gut-derived 5-HT taken up by
platelets is involved in a number of other processes. Circulating 5-HT plays a role in
vasoconstriction and vasodilation, clot formation, and red blood cell (RBC) survival.
As previously mentioned, one of the earliest known roles of 5-HT was as a vasoactive
compound found in serum (Rapport et al., 1948). Initially 5-HT was described as a
vasoconstrictor because it elevated vessel tone, but recent studies have shown that
chronic treatment with 5-HT actually causes a dose-dependent reduction in blood
pressure, likely mediated by the 5-HT7 receptor expressed on superior mesenteric veins
(Watts et al., 2015).
Along with modulating blood pressure, 5-HT is involved in the normal function of
RBCs both in circulation and in clot formation. Starting early in the 1970s, 5-HT was
thought to be involved in erythropoiesis (Lowy et al., 1970; Noveck and Fisher, 1971). It
has been shown that 5-HT promotes hematopoietic stem cells and supports the bone
marrow microenvironment (Yang et al., 2007). It has also recently been shown that 5-HT
circulating in RBCs is important for keeping RBCs from senescence and/or slows the
effects of aging in RBCs (Amireault et al., 2013). In TpH1 knockout mice, which lack
EC cell derived 5-HT, there is reduced gut and circulating 5-HT, reduced RBC lifespan,
reduced plasma anti-oxidant status, and reduced post-transfusion RBC survival rates
(Amireault et al., 2013). Furthermore, treating stored RBCs with 5-HT extends the viable
window for use and enhances survival post-transfusion (Amireault et al., 2013).
Amireault et al described the effects of 5-HT as anti-oxidant, due to the fact that there are
no 5-HT receptors detected on RBCs and 5-HT agonists did not yield the same effect.
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Overall, it appears that circulating 5-HT is critical for the maintenance of hematopoietic
stem cells, functional bone marrow, and the life span and quality of RBCs.
4. Bone
The 5-HT in platelets is not only working to mature RBCs and cause normal clotting, it
appears that it also plays a role in bone metabolism. Serotonin in the CNS acts to
promote bone growth by acting on 5-HT2C receptors in the ventromedial hypothalamic
nuclei, and is likely modulated in part by leptin (Yadav et al., 2009). Leptin released
from adipocytes signals to the ventromedial hypothalamus, inhibiting brainstem derived
5-HT release; normal release of CNS 5-HT in the hypothalamus encourages bone mass
accrual (Yadav et al., 2009).
In contrast to its actions in the CNS, peripheral 5-HT acts to limit bone formation
(Ducy and Karsenty, 2010). An intensely studied protein involved in bone remodeling is
LDL-receptor related protein 5, or Lrp5. Various studies with gain-of-function and lossof-function Lrp5 have shown significant changes in bone, and in fact, Lrp5 knockout
mice have severe osteoporosis. It is now known that Lrp5 is involved in osteoblast
formation, as the knockouts showed decreased expression of proliferation genes while
osteoclast markers were unchanged (Yadav et al., 2008). Currently, there are conflicting
reports on the direct role of 5-HT in bone metabolism.
Lrp5 is known to be a co-receptor of the Wnt/β-catenin pathway. However, when the
Karsenty group mutated β-catenin, it did not appear to alter bones, suggesting that Lrp5
and the β-catenin arm of the Wnt pathway may operate independently for bone
modulation through osteoblasts (Ducy and Karsenty, 2010). In a search for genes that
were upregulated in the Lrp5 knockout mice, Yadav et al found that TpH1 was increased,
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and thus, there was more 5-HT available to act as a signaling molecule (Yadav et al.,
2008). It was also found that a Gαi protein coupled receptor, the 5-HT1B receptor, inhibits
cAMP and PKA phosphorylation of CREB and other transcription factors, is expressed
on osteoblasts, providing a site of 5-HT modulation (Yadav et al., 2008; Ducy and
Karsenty, 2010). In fact, new therapies for osteoporosis are repurposing IBS drugs that
inhibit TpH1 (Yadav et al., 2010). In models of osteoporosis and osteopenia, oral
treatment with LP533401 reduced circulating 5-HT, improved bone volume metrics, and
did not appear to alter GI motility or blood clotting (Yadav et al., 2010; Inose et al.,
2011). Taken together, these reports suggest that 5-HT is acting on 5-HT1B receptors
expressed on osteoblasts and influencing Lrp5 function to modulate bone.
This appears to be controversial as Cui and others have demonstrated that 5-HT does
not modulate bone mass and that Lrp5 works through the Wnt/β-catenin pathway (Cui et
al., 2011; Korvala et al., 2012). In contrast, this group demonstrated that bone growth
therapeutics with TpH1 inhibitors were ineffective compared to the current anabolic
treatment, teriparatide (Cui et al., 2011). A potential source of difference may be the
TpH1 inhibitor used was a variation of LP533401, called LP923941, which the authors
describe as the active enantiomer of the compound. It is possible that the “inactive”
enantiomer also has some modulatory effect.
Alternatively, other groups have shown different methods by which 5-HT may be
modulating osteoblast activity. In one study, FOXO1 seems to be acting one way in
normal physiology through CREB (under typical circulating 5-HT conditions) and acts
oppositely in pathological conditions through AFT4 (under high circulating 5-HT
conditions) (Kode et al., 2012). When there is high circulating 5-HT and FOXO1 is
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disrupted from the typical association with CREB, it binds to AFT4 and upregulates
AFT4 responses ultimately resulting in cell cycle arrest. Another group has recently
demonstrated that there may be yet another mechanism by which 5-HT is modulating
bone metabolism. In osteoblast cultures, addition of 5-HT interferes with the assembly of
the plasma fibronectin (pFN) matrix, an important component of bone extracellular
matrix involved in normal osteoblast formation (Cui and Kaartinen, 2015). It appears
that 5-HT disrupts this matrix and prevents normal extracellular matrix stabilization and
mineralization (Cui and Kaartinen, 2015). These data suggest there are many ways that
circulating 5-HT may be directly or indirectly modulating bone.
In recent years it has come to light that patients taking SSRIs have decreased bone
mass and increased risk of fractures. Many studies have linked depression and treatment
for depression to osteoporosis, and that more severe levels of depression are correlated to
decreased bone mineral density (BMD) (Rizzoli et al., 2012). There are several factors
that could contribute to bone loss in depression: behavioral factors such as cigarette or
alcohol use, biological factors such as increased cortisol and inflammation, confounding
factors such as Crohn’s Disease (CD) or diabetes, and anti-depressant medication use
such as SSRIs (Mezuk et al., 2008). Any or all of these factors can influence 5-HT
signaling components, and thus alter bone metabolism. Mouse models lacking SERT or
those treated with SSRIs, effectively reducing SERT activity, also have reduced bone
growth (Warden et al., 2005). As previously mentioned, osteoblasts express 5-HT1B
receptors as well as SERT (Garfield et al., 2014). One example of potential biological
factors is that patients with a high expressing SERT or a low expressing 5-HT1B genotype
had reduced bone formation over 12 weeks of SSRI treatment (Garfield et al., 2014).
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Evidence from animal models of colitis, where it is known that circulating 5-HT is
high and SERT is down-regulated (Linden et al., 2003b; Coates et al., 2004; Linden et al.,
2005), also shows that there is rapid bone loss due to suppressed bone formation and
increased bone absorption (Hamdani et al., 2008). Furthermore, Harris and others have
shown that this bone loss is reversible when experimental IBD resolves; when dextran
sodium sulfate (DSS) is removed and animals are allowed to recover, bone structure and
size normalizes (Harris et al., 2009). Colitis models might have serious potential for
future comorbidity studies looking at systemic effects of IBD and altered bone
metabolism.
IV. Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is an umbrella term used to describe diseases of
the colon marked by inflammation. This term encompasses Crohn’s Disease (CD) and
Ulcerative Colitis (UC). Characteristic symptoms of each will be described for each in
subsequent sections. Currently, hundreds of thousands of people in the US alone suffer
from IBD, with adults incurring between $15,000-$18,000 in annual direct medical costs.
A. Inflammation
Inflammation is caused by recruitment of activated cells from both the innate and
adaptive immune systems. Damaged cells release chemical signals and cause nearby
immune cells such as macrophages and dendritic cells to respond to initiate
inflammation. These innate immune cells are then activated and release inflammatory
mediators including cytokines. The innate immune system handles the initial insult, after
which the innate system activates the adaptive immune system. The adaptive immune
system recognizes foreign bodies and “remembers” them for possible future infections.
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The adaptive immune cells include memory T and B lymphocytes. Cytokines help T
cells mature, and in the case of GI inflammation and immune response, T cells can
become either a helper T 1 (Th1) cell or a Th2 cell, both are CD4+ cells. Helper T 1 cells
stereotypically produce interferon-gamma (IFN-γ) and lead to cell-mediated immunity
via activating B cells to make opsonizing antibodies. The Th1 response is usually
employed against intracellular pathogens and as previously mentioned is the route of
inflammation in CD (Shih and Targan, 2009). Helper T2 cells stereotypically produce
interleukin-4 (IL-4) and cause B cells to make neutralizing antibodies. This route is often
observed with extracellular pathogens and is associated with UC (Shih and Targan,
2009).
B. Crohn’s disease
Crohn’s disease causes transmural (through the gut wall) ulceration on parts of the GI
tract ranging from the duodenum to distal colon (Baumgart and Sandborn, 2012).
Although inflammation can occur anywhere along the GI tract, it most commonly occurs
in the small intestine and right side of the colon, and one of the characteristic features of
Crohn’s is a “skipping” pattern in which regions of inflammation are interspersed with
regions without inflammation. Major symptoms of CD include abdominal pain, bloody
stool, persistent diarrhea, and weight loss.
B. Ulcerative Colitis
Ulceration of the tissue in UC is non-transmural, it is limited to the mucosa, and
occasionally the submucosa, and is regionally limited to the large intestine, particularly
the left side of the colon (Ordas et al., 2012). UC involves the activation of CD4+
lymphocytes and is associated with high levels of transforming growth factor (TGF-β)
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and interleukin-5 (IL-5) (Podolsky, 2002). Major symptoms associated with UC include
bloody diarrhea and bouts of severe abdominal pain. Although UC is not often directly
life threatening, it does appear to increase the risk of colorectal cancer. Data obtained
from patients with UC show that there is a reduction in the availability of serotonin in the
colonic mucosa, the release of serotonin is unchanged but SERT expression is reduced
(Coates et al., 2004).
C. Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a functional GI disorder (FGID) that is
characterized by pain, bloating and altered bowel habits in the absence of altered colon
morphology or alarm signs such as bleeding or being awakened from sleep. To diagnose
IBS, patients must meet a set of conditions referred to as the “Rome III Criteria” that was
established by gastroenterologists and neurogastroenterologists to unify FGID diagnoses.
Irritable bowel syndrome is clinically diagnosed in at least 2 per 100 people in the US,
and the actual number is probably much higher (speculated at 10-15% of the population)
as many IBS sufferers choose not to seek medical treatment (Locke et al., 2004). In
another study, Quigley et al. stated that 14% of the Euroean population had active IBS
symptoms (Quigley et al., 2006). Europeans also have a relatively high prevalence of IBS
and it is estimated that over one third of those suffering from IBS seek medical treatment
(Quigley et al., 2006). IBS has been linked to altered serotonin signaling, including a
decrease in SERT expression (Coates et al., 2004) and pharmaceuticals that target
specific serotonin receptors alleviate symptoms of IBS with constipation (IBS-C) and
IBS with diarrhea (IBS-D) (Mawe and Hoffman, 2013).
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V. Animal models of colitis
There is no animal model that perfectly reflects all the properties of IBD. Thus,
several models have been described and used to mimic features of IBD, including
inflammation and dysmotility. Frequently used and well-studied models of colitis include
2,4,6-trinitrobenzene sulfonic acid (TNBS), Trichinella spiralis, Citrobacter rodentium,
and dextran sulphate sodium (DSS). Recently, other models such as the interleukin-10
(IL-10) knock out have been introduced as potential models for studying unique
components of the inflammatory-dysmotility-hypersensitivity process (Scheinin et al.,
2003).
A. DSS
Dextran sodium sulfate (DSS) has been described as a polyclonal B and T cell
activator (Ni et al., 1996), but DSS can induce colitis in immune-deficient mice as well,
suggesting that B and T cells are not required for the development of DSS-colitis and
demonstrating that DSS colitis involves an innate immune response (Dieleman et al.,
1994). The mechanism by which DSS exerts its effect is by initiating the nucleotidebinding domain and leucine-rich containing (NLR) family of receptors that recognizes
many pathogen-associated molecular patterns and induces an inflammatory response
(Wirtz et al., 2007; Bauer et al., 2010; Perse and Cerar, 2012). Administration of DSS
can induce an acute phase of inflammation, and with long-term administration (7 days) in
drinking water it can induce a chronic inflammation that in the absence of DSS for 5
weeks still shows incomplete healing (Dieleman et al., 1994).
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B. TNBS
Trinitrobenzene sulfonic acid (TNBS) induces a Th1 cytokine driven immune
response through haptenization (Wirtz et al., 2007). This method of single dose
inflammation induction has acute and chronic phases, is similar to IBD both
histopathologically and immunologically, and seems to be a good model for Crohn’s
disease. TNBS is administered with alcohol to break down the mucosal barrier to allow
for TNBS infiltration and results in ulceration, edema, hyperemia and changes in the
cyto-architecture of the mucosa. It is interesting to note that although these animals
experience colonic inflammation and dysmotility well after administration of TNBS, they
regain the ability to gain weight and the epithelium barrier is quickly repaired, suggesting
that the colitis has transitioned from acute to a chronic inflammatory state.
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VI. Specific Aims
Inflammatory Bowel Disease (IBD) is an umbrella term that describes gastrointestinal
diseases such as Crohn’s Disease (CD) and ulcerative colitis (UC). The hallmark of IBD
is inflammation of the colon, which can result in dysmotility as well as visceral pain and
discomfort. In the past, 5-HT4 receptor agonists have been used as prokinetic agents to
treat constipation, but due to systemic side effects, they are not readily available in the
USA. Recently we have shown that 5-HT4 receptors are highly expressed in the mucosa
of the colon, and activation of mucosal 5-HT4 receptors elicits secretion of 5-HT, mucus,
and Cl- from epithelial cells. Furthermore, luminal administration of 5-HT4 agonists has
prokinetic and anti-nociceptive effects. We hypothesize that mucosal activation of the 5HT4 receptors has a protective effect against inflammation and the associated dysmotility
and visceral hypersensitivity observed in colitis.
Specific Aim 1: We will test whether in vivo administration of 5-HT4 agonists to the
lumen of the colon attenuates the development of, and/or reverses, experimental colitis.
We will use two mouse models of colitis, both of which share properties of IBD and will
allow us to evaluate the effects of mucosal 5-HT4 agonists in the development of colitis.
We hypothesize that the luminal administration of the 5-HT4 agonists attenuates the
development of, and accelerates recovery from, inflammation in experimental colitis.
1.1: We will confirm that DSS and TNBS mouse models result in repeatable levels of
inflammation. We will evaluate the effects of 5-HT4 agonists applied intraluminally
during and after the development of inflammation in each of these models. We will
measure and track body weight, disease activity index, and we will use a microscopic
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scoring system to evaluate the effect of 5-HT4 agonist treatment on inflammation on
tissue grossly and with histology.
1.2: We will examine the actions of 5-HT4 agonists on inflammation in the presence of 5HT4 antagonists in order to confirm the involvement of the 5-HT4 receptors in protective
actions that we detected.

Specific Aim 2: We will test the actions of 5-HT4 receptor stimulation in epithelial cells
of the inflamed colon. The protective effects of activation of 5-HT4 receptor could be due
to an increase in epithelial barrier function. We hypothesize that mucosal activation of
these receptors can improve barrier function and increase mucus secretion in inflamed
animals.
2.1: We will examine the effects of mucosal 5-HT4 receptor activation on epithelial cell
proliferation, wound healing, and oxidative stress.

Specific Aim 3: We will test whether treatment with 5-HT4 agonists improves colonic
motility in models of colitis. In humans and experimental animals, colitis is associated
with disrupted motility. Previously, 5-HT4 agonists have been used to treat constipation,
and we have recently demonstrated that luminal administration of 5-HT4 agonists
accelerates motility. We hypothesize that mucosal activation of these receptors can
restore normal motility in animals with colitis.
3.1: We will examine changes in propulsive motility in the TNBS guinea pig model with
continuous treatment with 5-HT4 agonists administered to the mucosa, and we will
determine the effects of 5-HT4 antagonist treatment on the actions of the agonist.
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Specific Aim 4: Test whether 5-HT4 receptor activation under basal conditions has a
protective effect on the epithelium. We will inhibit mucosal 5-HT4 receptor activity with
an antagonist in normal animals to examine if endogenous 5-HT signaling at the 5-HT4
receptor contributes to the steady state health and function of the colon. We hypothesize
that endogenous 5-HT acts on 5-HT4 receptors to limit the extent of physiological
inflammation.
4.1: We will examine the development and recovery from colitis in 5-HT4 receptor
knockout mice using the same measures as aim 1.
If mucosal activation of the 5-HT4 receptor can attenuate the inflammation and
dysmotility found in colitis models it would provide a novel target for human IBD
therapies.
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CHAPTER 2: PROTECTIVE ACTIONS OF 5-HT4 RECEPTORS IN THE
COLONIC EPITHELIUM
ABSTRACT
Background: 5-HT4 receptors are expressed in colonic epithelium, and activation with
5-HT4 receptor agonists causes a number of responses, including mucus secretion from
goblet cells, chloride secretion from enterocytes, and 5-HT release from enterochromaffin
cells. We tested whether this receptor could serve a protective role in models of colitis
and under basal conditions.
Methods: Male CD-1 mice (Charles River, Canada) were administered DSS (4% w/v in
tap water, MW: 40,000) or TNBS (7.5mg/mL in 50% ethanol by enema) on day 0.
Treatment with the 5-HT4 receptor agonist, tegaserod (1 mg/Kg), or agonist plus the
antagonist, GR113808 (1 mg/Kg), began either 24 hours after colitis induction and
continued daily for 6 days (prevention paradigm), or 5 days after colitis was induced and
continued for 10 days (recovery paradigm). To test for an action of 5-HT4 receptors
under basal conditions, the antagonist, GR113808 was administered to normal mice by
daily enema for 10 days. Colitis was evaluated using disease activity index (DAI) and
histological damage scores (HDS). Possible protective mechanisms such as improved
epithelial barrier function through evaluation of cell proliferation by Ki-67
immunostaining, whereas cell migration and resistance to oxidative stress were explored
in CaCo-2 cells. We also tested the effects of tegaserod and/or GR113808 on colonic
motility in guinea pigs.
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Results: Treatment with Tegaserod by enema in both DSS and TNBS-inflamed animals
significantly attenuated the development of colitis (DAI, p<0.05; HDS, p<0.001 for DSS;
DAI, p<0.05 for TNBS), and accelerated recovery from established colitis (DAI,
p<0.0001; HDS p<0.0001 for DSS, DAI, p<0.0001; HDS, p<0.01 for TNBS), and these
effects were blocked by 5-HT4 antagonist treatment. This effect was not seen when
Tegaserod was administered by intraperitoneal injection. TNBS-induced dysmotility in
guinea pigs was significantly reversed by 5-HT4 receptor agonist treatment, but
dysmotility persisted in animals treated with the agonist plus antagonist. We observed
significant increases in the proportion of epithelial cells that were Ki-67 positive in DSSinflamed mice treated with the agonist (p<0.05), and this effect was blocked by the
antagonist. In CaCo-2 cells, 5-HT4 receptor activation accelerated cell migration into
scratches on cell cultures, and increased resistance to oxidative stress-induced apoptosis,
and these effects were blocked by the antagonist. Furthermore, treatment with the
antagonist alone resulted in significant increases in disease activity index (p<0.0001),
histological damage scores (p<0.0001) and bacterial translocation in mice, and led to
disrupted motility patterns in guinea pig distal colon.
Conclusions: 5-HT4 receptor stimulation reduced the development of, and accelerated
recovery from, inflammation. These effects likely involved improved wound healing and
resistance to oxidative stress. Interestingly, inhibition of 5-HT4 activity in normal
animals resulted in inflammation, decreased epithelial proliferation and disrupted
motility. Taken together, these data suggest that activation of mucosal 5-HT4 has a
protective effect in the normal and the inflamed colon.
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INTRODUCTION
It is well established that serotonin (5-hydroxytryptamine, 5-HT) acts as a
neurotransmitter in both the central and peripheral nervous systems, and as a paracrine
signaling molecule in the periphery (Berger et al., 2009). While its role is often thought
of as a brain neurotransmitter, over 90% of the 5-HT in the body is made and found in the
gastrointestinal (GI) tract (Mawe and Hoffman, 2013). This gut-derived 5-HT is
responsible for many GI functions such as motility, secretion and vasodilation, and
activation of sensory signals from the gut to the brain and spinal cord (Bulbring and
Crema, 1958; Bulbring and Lin, 1958; Leung et al., 1995; Keating et al., 2008). In
addition, 5-HT has also been shown to have neuro-protective (Liu et al., 2009) and proinflammatory actions in the gut (Li et al., 2011; Kim et al., 2013). Because of its
importance as an activator of gut reflexes and sensory signals, and because a variety of 5HT receptors subtypes are distributed through the enteric neural circuitry, drugs targeting
5-HT receptors have been developed for the treatment of GI functional disorders and pain
(Mawe and Hoffman, 2013).
There are seven families of 5-HT receptors and 14 or more subtypes, so it’s
reasonable that 5-HT could have many roles and many mechanisms by which it exerts its
effect (Nichols and Nichols, 2008). At least 5 different 5-HT receptor subtypes are
located in the wall of the gut, and one of these is the 5-HT4 receptor. The 5-HT4 receptor
is a seven transmembrane receptor that is G-protein coupled which activates adenylate
cyclase and is constitutively active (Bockaert et al., 2008). In addition to being located
on enteric nerve terminals where its activation promotes transmitter release, it has been
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recently demonstrated that 5-HT4 receptors are widely expressed in colonic epithelial
cells (Hoffman et al., 2012). When introduced into the lumen of naïve animals, 5-HT4
receptor agonists cause chloride secretion and goblet cell degranulation, as well as
increase colonic propulsive motility and reduce visceral hypersensitivity (Hoffman et al.,
2012).
Agonists of the 5-HT4 receptor have been used as prokinetic and anti-nociceptive
agents for constipation predominate irritable bowel syndrome (IBS-C). In addition to
their ability to promote synaptic transmission through a presynaptic mechanism, 5-HT4
receptors in the gut appear to mediate protective effects that extend beyond their role in
synaptic transmission. For example, pretreatment with 5-HT4 receptor agonists can
reduce the extent of NSAID induced inflammation, and that this effect is seen at doses
lower than those used to elicit prokinetic actions (Fujisawa et al., 2010). Furthermore,
agonists acting on 5-HT4 receptors are capable of stimulating enteric neurogenesis and
promoting axon growth in vitro (Liu et al., 2009) and in vivo, 5-HT4 receptor agonists
promote the restoration of the recto-anal reflex in resected colon preparations (Takaki et
al., 2014). The endogenous role of the 5-HT4 receptor is still being determined, but it
appears to play a significant role in the development and survival of enteric neurons (Liu
et al., 2009).
The aim of this investigation was to explore the hypothesis that mucosal stimulation
of the 5-HT4 receptor in animal models attenuates the development of, and improve the
recovery from, experimental colitis. To test this hypothesis we assessed two separate
paradigms: inflammation prevention and inflammation recovery. We used both dextran
sodium sulfate (DSS) and trinitrobenzene sulfonic acid (TNBS) models of colitis to best
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mimic ulcerative colitis and Crohn’s disease, the two most prominent types of IBD. We
tracked disease progression using the disease activity index (DAI), a measure that takes
into account symptom features such as weight loss, stool consistency and presence of
fecal blood (Cooper et al., 1993). To confirm inflammation and changes due to agonist
treatment, we assessed histological damage scores. Histology scores are based on criteria
GI pathologists use to determine type and extent of IBD in human patients (Villanacci et
al., 2013). To explore possible mechanisms by which 5-HT4 receptor activation exerts its
effect, we used immunofluorescence for Ki-67 positive cells to examine cell
proliferation, and we used CaCo-2 cell cultures to investigate the effects of 5-HT4
receptor stimulation on wound healing and resistance to oxidative stress. Colonic
propulsive motility and colonic clearance patterns were examined in treated and untreated
inflamed animals. Finally, we tested whether 5-HT activation under basal, healthy
conditions influences the integrity of the epithelial layer. Our findings suggest that
stimulation of the 5-HT4 receptor has protective effects against inflammation, dysmotility
and visceral hypersensitivity in models of colitis.
METHODS
Animal Preparations
All experimental protocols were approved by the Institutional Animal Care and Use
Committee of the University of Vermont, and the University of Calgary Animal Care
Committee. In all cases, animals were euthanized by isoflurane overdose and
exsanguination or cervical dislocation.
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Male CD-1 IGS mice aged 7-8 weeks were purchased from Charles River (Canada)
and used for all assays except motility and intracellular recordings. Male Hartley guinea
pigs weighing between 250-300 g were purchased from Charles River (Canada) and were
used for colonic motility and intracellular recordings.
Induction of Colitis
To induce dextran sodium sulfate (DSS) colitis, 4% (w/v; MW: 40,000) DSS was
dissolved in tap water. Animals consumed 4% DSS-containing water for 5 days and then
were returned to regular tap water for 2-10 days. To induce trinitrobenzene sulfonic acid
(TNBS) colitis, animals were lightly anesthetized and a single colonic enema of TNBS in
ethanol was delivered. Mice received 7.5mg/mL TNBS in 50% ethanol with a final
volume of 100uL per mouse inserted approximately 3 cm past the rectum, and guinea
pigs received 25mg/mL in 30% ethanol with a final volume of 300uL per guinea pig
inserted approximately 7 cm past the rectum. Animals were weighed daily to track
changes in weight and evaluated for signs of distress.
Experimental Paradigms
We used two different experimental paradigms: prevention and recovery. For the
prevention experiments, mice were on DSS for 5 days and then switched to tap water or
were given a single enema of TNBS. Daily enemas with either vehicle or drug were
started 24 hours after induction. The recovery paradigm required colitis to be established
before beginning treatment, therefore treatment began 5 days after initial DSS or TNBS
induction.
Gross Assessment of Inflammation
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Severity of colitis was monitored using the disease activity index (Cooper et al.,
1993). Briefly, disease activity index accounts for weight loss (up to 5%=1, 5-10%=2,
10-20%=3, >20%=4), stool consistency (normal stool=0, soft stool=2, diarrhea=4) and
presence of fecal blood (negative hemoccult=0, positive hemoccult=2, gross bleeding=4).
Weight loss comparisons were made to day 0 weights. Presence of fecal blood was
determined using Hemoccult Single Slide testing slides from Beckman Coulter (Brea,
CA). After euthanasia, tissue was collected and fixed for IHC or flash frozen.
Histological Assessment of Inflammation
Tissue from inflamed mice was fixed by immersion in 4% paraformaldehyde in 0.1M
phosphate buffer overnight at 4°C. Tissue was then paraffin-embedded, sectioned at 10
μm, and stained with hematoxylin and eosin (H&E). With the aid of a gastrointestinal
pathologist, a scoring rubric based on histological features of human IBD was developed
(Villanacci et al., 2013). Briefly, this score reflects epithelial damage, altered crypt
architecture, infiltration of mono and poly-morphonuclear cells into the lamina propria
and epithelium, evidence of ulcers or erosions, and presence of granulomas. Two slides
for each experimental condition were scored blinded to treatment.
Immunohistochemistry
Serial sections adjacent to those used for H&E were used for IHC. Slides were
deparaffinized using xylene and a series of ethanol washes. Antigen retrieval was
performed to improve staining. Slides were blocked in 4% goat serum in 0.5% Triton-X
in phosphate buffered saline (PBS), slides were incubated in rat anti-mouse Ki-67 (1:100;
eBioscience, San Diego, CA) in PBS with 0.5% Triton-X, rinsed, then incubated in goat
anti-rat Cy3 antibody (1:600; Jackson ImmunoResearch, West Grove, PA). Slides were
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counterstained with DAPI (1:10,000), a nucleic acid marker, to determine total number of
cells. The data are presented as percentage of Ki-67 positive cells compared to total
number of cells per crypt (Joly et al., 2009). Images were produced on an Olympus
AX70 fluorescence microscope and captured using an Optronics MagnaFire digital
camera and accompanying software.
Motility
Colonic motility was examined in control and TNBS inflamed guinea pigs (Hoffman
et al., 2010). After 6-7 days of vehicle or treatment, animals were euthanized and the
colons were quickly dissected out and placed in oxygenated Krebs solution on ice. The
most distal 5-10 cm of colon was placed in the organ bath of the GastroIntestinal Motility
Monitor (GIMM; Catamount Research and Development, St. Albans, VT). The tissue
was allowed to equilibrate and empty for 30 minutes in circulating warmed (37°C) Krebs
at a flow rate of 10 ml/min. Mesentery and fat were then cleared from the tissue and it
was pinned at either end onto the Sylgard-lined (Dow Corning Co, Midland, MI) organ
bath. An epoxy-coated fecal pellet was introduced into the oral end of the colon and,
using a video camera mounted above, the rate of propulsive motility was recorded and
analyzed using the GIMM software. At least five trials were performed for each segment
of colon with a 5-minute rest period between trials. Motility was measured over the
entire length of the colon. Clearance patterns were determined by recording if the pellet
exited the colon within the 5-minute trial period.
Intracellular Recording
Intracellular recordings of membrane potentials were carried out as previously
described (Roberts et al., 2013). Briefly, the distal colon of guinea pigs was removed and
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dissected in iced Krebs solution by opening the colon along the mesenteric border. The
mucosa and submucosa were dissected free from the underlying circular muscle. The
tissue was then pinned in a Sylgard-lined recording chamber with a circulating warmed
(37°C) aerated Krebs solution bath containing nifedipine (5 µM; Sigma-Aldrich) to limit
smooth muscle contractions. Glass microelectrodes, with resistances ranging from 70 to
120MΩ, were filled with 2M KCl and utilized to impale the circular smooth muscle cells
of the tissue at random under visualization with an inverted microscope at 100X
magnification.
Transmural stimuli (0.5ms pulse duration, 0.5Hz, 50V) were delivered to activate
junction potentials. Since there is polarity to the enteric circuitry, microelectrodes
impaled the tissue aborally to the transmural stimulation to record evoked inhibitory
junction potentials (IJPs). These voltage recordings were obtained with an Axoclamp-2A
amplifier (Axon-instruments, Union City, CA, USA) and analyzed with PowerLab Chart
(version 5.01; AD Instruments, Castle Hill, NSW, Australia).
Cell lines culture and treatment for oxidative stress
Human Caco-2 cells, a common epithelial colorectal adenocarcinoma cell line used
for in vitro gut studies (ATCC, UK) were maintained in a humidified atmosphere of 95%
air and 5% CO2 at 37°C in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/ml penicillin and 100
Ag/ml streptomycin. In order to produce oxidative stress in CaCo-2, H2O2 was freshly
prepared from 30% stock solution prior to each experiment. Cells were treated with
specified concentrations (200 µM) of H2O2 in phosphate-buffered saline (PBS) for 30
min (Clement et al., 1998) 24 h after the cells were seeded.
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Cytotoxicity assay
The sulforhodamine B (SRB) assay is used for cell density determination, based on
the measurement of cellular protein content. The method described here has been
optimized for the toxicity screening of compounds to adherent cells in a 96-well format.
The results are linear over a 20-fold range of cell numbers and the sensitivity is
comparable to those of fluorometric methods (Vichai and Kirtikara, 2006).
Cells (100 µL, 1 × 105 cells / mL) were pre-seeded into 96-well plates and incubated
for 24 h. To determine the cytotoxicity profiles of the two 5-HT4 agonists, the SRB assay
was performed by incubating cells for 0 (untreated), 30 and 60 minutes with prucalopride
(Shire, Ireland) or tegaserod (Sigma-Aldrich) at final concentrations ranging from 10 pM
to 10 mM. Vehicle controls were exposed to 0.05% (v/v) DMSO in culture medium while
wells containing only culture medium served as blanks.
For SRB assay, after 1 hour of exposure period, supernatant was aspirated from wells
and cells were fixed with cold trichloroacetic acid (TCA) solution (30% w/v) at 4°C for 1
h. After incubation, the plate was gently washed with water and dried in a lowtemperature oven, after which SRB solution was added to stain the cellular protein
contents. Following washing with 1% acetic acid solution (v/v) to remove excess of
unbound dye, plates were allowed to dry and dissociated using a 10 mM Tris base
solution (pH 10.5). Absorbance was measured at 540 nm with a reference wavelength of
630 nm, using spectrophotometry.
Scratch Assay
CaCo-2 cells (kindly provided by Dr. J Turner, University of Chicago) were cultured
in 6 well plates to confluence in DMEM high glucose supplemented with 10% FBS, 1%
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GlutaMAX, 10mM Hepes and 100U/ml Penicillin-Streptomycin (ThermoFisher Grand
Island, NY), . Wounds were created using a sterile pipet tip, dragged perpendicular to a
black line drawn on the bottom of the dish for reference. Images were captured at 0 and
48 h with a Nikon D7100 camera connected to a Nikon Daphot inverted microscope.
Measurements were taken from edge to edge at time 0h and compared to measurements
from 48 h. The reported values are the difference between 0 h and 48 h, with higher
values representing more healing.
Bacterial Translocation
After euthanasia, mice were wiped down with sterile alcohol wipes and spleen and
liver were removed using clean tools. Spleen and liver samples were weighed and
homogenized in 1 mL sterile PBS. Between samples the homogenizer was rinsed in
sterile PBS, water, then 70% ethanol to prevent cross contamination. Aliquots of 200 μL
homogenate were plated on Columbia and MacConkey agar plates (Daelynn Biologics,
Calgary, AB) and incubated at 37°C in 5% CO2. After 48 h, the number of positive
plates and the approximate number of bacterial colonies was determined per gram of
tissue; contaminated plates were not counted.
Data Analysis
The data are shown as mean ± SEM for n number of animals. Statistical analyses
were performed using the software GraphPad Prism (version 6.0c, GraphPad Software,
La Jolla, CA, USA). Significance was determined using unpaired student’s t-test, 1-way
ANOVA or 2-way ANOVA with comparisons across all groups, with Bonferroni’s
correction, or Fisher’s exact test, when appropriate. p-values less than 0.05 were
considered statistically significant.
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RESULTS
Effects of Epithelial 5-HT4 Receptor Stimulation on Colitis
To test whether activation of epithelial 5-HT4 receptors elicits a protective action in
the inflamed colon, two models of colitis, and two experimental paradigms were
investigated (Supplemental Fig. 1). The DSS and TNBS models of colitis were used
because they mimic several prominent clinical and morphological features of ulcerative
colitis (Gaudio et al., 1999; Strober et al., 2002) and Crohn’s disease (Elson et al., 1995),
respectively. In the first paradigm, the 5-HT4 agonist was administered during the
development of colitis, and in the second, the agonist was administered after colitis had
already been established. Colitis was evaluated by determining the disease activity index
(DAI) and histological damage score (HDS).
5-HT4 Receptor stimulation attenuates the development of colitis
To test the effect of 5-HT4 receptor stimulation on the development of colitis, mice
received daily enemas of tegaserod (1 mg/Kg) beginning on day 1 (Fig. 1). In DSSinflamed mice, treatment with the agonist significantly reduced the DAI (p<0.05) and the
HDS (p<0.001) compared to vehicle (1% DMSO in 0.9% saline) treated DSS inflamed
animals (Fig 1.; n=9-10 per group). The protective effect of tegaserod was blocked in
animals that were also treated with the 5-HT4 antagonist, GR113808 (DAI, p<0.05; HDS,
p<0.0001; n=5).
In the TNBS model of colitis, treatment with the agonist significantly reduced the
DAI as compared to inflamed controls (p<0.05; n=7 per group). However, in this model,
treatment with the agonist did not significantly improve the histological damage scores.
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The protective effect of tegaserod on the DAI was attenuated by the 5-HT4 antagonist
(p<0.02 by t-test; n=7).
5-HT4 receptor stimulation accelerates healing from established colitis
To test whether activation of epithelial 5-HT4 receptors in the distal colon affects the
recovery from colonic inflammation, animals were treated with the 5-HT4 agonist after
colitis was established (Fig. 2). In these experiments, animals were induced with DSS or
TNBS and allowed to develop colitis for 5 days prior to 10 days of daily enema
treatments. Colitis and recovery was evaluated using DAI and HDS.
In DSS-inflamed animals, treatment with the agonist significantly improved the
recovery as compared to vehicle treated animals (p<0.0001 at day 15; n=22-23 per
group). Furthermore, DSS-inflamed mice treated with tegaserod showed significant
(p<0.0001) improvement in HDS as compared to vehicle treated animals. Treatment with
the 5-HT4 antagonist prevented recovery from colitis in tegaserod treated animals (DAI,
p<0.001; HDS, p<0.001; n=5).
In TNBS-inflamed animals, treatment with the agonist significantly improved
recovery as compared to vehicle treated animals (p<0.001 at day 15; n=14-16 per group).
Furthermore, TNBS-inflamed mice treated with tegaserod showed significant
improvement in HDS as compared to vehicle treated animals at day 15 (p<0.01).
Pretreatment with the antagonist inhibited the effects of tegaserod on the DAI measures
(p<0.001; n=8), and HDS (p<0.05 by t-test; n=13).
Intraperitoneal administration of the 5-HT4 receptor agonist fails to affect colitis
It is possible that the protective actions described above could involve non-epithelial
5-HT4 receptors via absorption and systemic distribution of the agonist. To test this
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possibility, the agonist was delivered daily by IP injection at the same dose (1 mg/Kg)
beginning on day 1. In DSS-inflamed animals, tegaserod administered IP failed to exert a
significant effect on the DAI or HDS (Fig. 3; n=7-8 per group).
Potential Mechanisms of Protection through 5-HT4 Receptor Activation
There are a number of ways that epithelial 5-HT4 receptor activation might act to
mediate the protective effects that were described above. These include maintenance or
reestablishment of the epithelial barrier through cell proliferation and migration, and also
by increasing resistance to epithelial apoptosis induced by oxidative stress. As the DSS
recovery paradigm yielded the most robust data regarding the protective actions of 5-HT4
receptor activation, this model was used to evaluate epithelial cell proliferation. The
effects of 5-HT4 receptor activation on epithelial migration and resistance to oxidative
stress were tested in CaCo-2 cells, a human adenocarcinoma cell line that is commonly
used for investigating epithelial cell biology. Prior to these experiments, we used rtPCR
and immunoblot techniques to confirm that CaCo-2 cells express the 5-HT4 receptor (data
not shown).
5-HT4 receptor activation improves wound healing
To test whether epithelial 5-HT4 receptor activation affects epithelial proliferation,
epithelial immunoreactivity for Ki-67, a nuclear protein that serves as an effective marker
of post-mitotic cells (Su et al., 2009), was evaluated and quantified as the percentage of
colonic gland epithelial cells that were Ki-67-immunoreactive. In the colons of DSSinflamed animals that were treated daily with tegaserod beginning on day 6, there was a
significant increase in the percentage crypt epithelial cells that were Ki-67 positive at day
15 compared to vehicle-treated DSS-inflamed animals (Fig. 4; p<0.05, n=9-10 per
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group). Furthermore, this proliferative effect of tegaserod was blocked by daily treatment
with the 5-HT4 antagonist (p<0.01, n=9). The proportion of epithelial cells
immunoreactive for Ki67 was also significantly higher in colons from animals treated
with tegaserod beginning on day 1 and euthanized on day 7 (p<0.001; n=5 per group).
In addition to epithelial proliferation, another mechanism that could contribute to
healing of epithelial erosions is increased epithelial cell migration (Heath, 1996). To test
if enterocyte 5-HT4 receptor activation affects epithelial migration, the healing rate of
scratches made in monolayers of CaCo-2 cells was evaluated over a 48 hour period. A
significant increase in the rate of scratch closure was detected in cultures treated with
tegaserod (1 µM) as compared to vehicle treated cultures (Fig. 5A and C; p<0.001; n=6).
This effect of tegaserod on epithelial migration was inhibited in the presence of the
antagonist (p<0.05; n=6).
It is known that oxidative stress is a feature of colitis in experimental animals and in
IBD (Shi et al., 2011), and that oxidative stress can trigger epithelial apoptosis (Becker et
al., 2013; Novak and Mollen, 2015). To determine whether 5-HT4 receptor activation is
protective against the effects of oxidative stress, CaCo-2 cells were exposed to the free
radical donor, H2O2 (200 µM) and percent cell survival was determined using the SRB
assay. Cultures treated with H2O2 showed a significant reduction in cell survival
compared to untreated cells (Fig. 5B; p<0.001; n=4). Cells treated with tegaserod (10
μM) showed significant protection from oxidative stress in cells exposed to H2O2
(p<0.001; n=4). Furthermore, the agonist-mediated protection from oxidative stress was
blocked by the antagonist, GR113808 (10 nM) in the presence of tegaserod compared to
agonist-treated cultures (p<0.001; n=4).
56

Effects of 5-HT4 Receptor Activation on Propulsive Motility
A common feature of IBD is altered GI motility (Reddy et al., 1991; Brierley and
Linden, 2014). We have used the TNBS model of colitis in guinea pig to characterize the
effects of inflammation on colonic motility (Linden et al., 2004; Strong et al., 2010;
Hoffman et al., 2011; Roberts et al., 2013), and we have demonstrated that changes in
enteric neuronal excitability (Hoffman et al., 2011) and purinergic inhibitory
neuromuscular transmission (Roberts et al., 2013) contribute to disrupted motility. We
therefore used this model to test whether 5-HT4 receptor activation results in improved
colonic motility. TNBS-inflamed guinea pigs were treated intraluminally with the
agonist daily for 6 days beginning 24 hours after TNBS instillation, colonic propulsive
motility and motility patterns were evaluated using the GIMM (Hoffman et al., 2010) and
intracellular recordings of evoked inhibitory junction potentials were measured..
Consistent with previous results (Linden et al., 2003a; Strong et al., 2010; Hoffman et
al., 2011; Roberts et al., 2013) the distal colons of TNBS-inflamed animals exhibited a
significant reduction in the rate of propulsive motility, and an increase in trials in which
fecal pellets became obstructed, as compared to those of healthy controls (Fig. 6; rate of
motility, p<0.0001, ANOVA; obstructions, p<0.0004, Fisher’s Exact Test; n= 6-8 per
group). Daily treatment with tegaserod significantly increased the rate propulsive
motility in TNBS inflamed colons (p<0.0001; n=6), and eliminated the obstructions that
are a feature of TNBS colitis. Antagonist treatment blocked the protective effect of
tegaserod, resulting in a significantly reduced rate of colonic propulsive motility
compared to agonist treated animals (p<0.0001, n=4). Furthermore, the antagonist
treatment resulted in an increase in the percentage of trials in which the pellets were
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obstructed, as compared to tegaserod treated preparations (p<0.0001, Fisher’s Exact
Test), as well as vehicle-treated TNBS inflamed preparations (p=0.0012, Fisher’s Exact
Test). Disrupted motility is partially attributed to reduced inhibitory junction potentials
(IJPs) in guinea pig TNBS-colitis. Daily treatment with tegaserod significantly improved
the IJP in TNBS inflamed animals compared to vehicle treated TNBS animals (Fig. 7;
p<0.0001).
Epithelial 5-HT4 receptors play a protective physiological role in healthy animals
The findings described above indicate that 5-HT4 receptor activation decreases the
extent of colitis as it develops, and accelerates recovery from colitis once it has been
established. These results raise the possibility that 5-HT4 agonists targeting the colonic
epithelium could provide a novel therapeutic approach for the treatment of colitis. These
results also raise the possibility that 5-HT4 receptors play a role in maintaining the
integrity of the epithelial layer under normal, healthy conditions. To test this, normal,
non-inflamed mice and guinea pigs were treated for 10 days with the 5-HT4 antagonist,
GR113808, administered by enema.
5-HT4 receptor antagonism reduces barrier function and results in inflammation
In animals that were treated with the antagonist alone, the methods that were used to
evaluate the protective actions of 5-HT4 receptor stimulation in the colitis models were
used to evaluate the health of the animals and the inflammatory state of the mucosal
layer. Treatment with the antagonist alone caused a significant increase in the DAI as
compared to vehicle treated controls (Fig. 8; p<0.0001, n=10 per group), and
histologically, inhibition of 5-HT4 receptor activation resulted in a significant increase in
the HDS (p<0.0001).
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It is possible that the inflammation observed in response to antagonist treatment is
associated with weakened barrier function, which would allow macromolecules and
bacteria to penetrate the epithelial layer, thus contributing to increases in DAI and HSD.
Epithelial integrity was investigated using Ki-67 immunoreactivity. In animals treated
with the antagonist alone, there was a significant reduction in Ki-67 immunoreactivity
compared to vehicle-treated controls (Fig. 9A; p<0.0001; n=8-10 per group). Evaluation
of bacterial translocation from the gut to either the spleen or the liver has been shown to
be an effective assay to evaluate this condition (Deitch et al., 1992; MacEachern et al.,
2015). In animals treated with the antagonist alone, there was a significant increase in
the number of cultures that were positive for bacterial translocation as compared to
vehicle-treated animals (Fig. 9B; p<0.02; n=3-5 per group).
Chronic inhibition of epithelial 5-HT4 receptors disrupts motility
To test whether endogenous 5-HT4 receptor signaling is involved in normal colonic
propulsive motility, guinea pigs were treated daily for 10 days with the antagonist alone
and the velocity and motility patterns were observed. Treatment with the antagonist did
not have a significant effect on propulsive motility through the colon, however, 25% of
trials did become obstructed, which was significantly different from control motility
patterns (Fig. 10; p=0.0035, Fisher’s Exact Test; n=5-6 per group).
DISCUSSION
This study was performed to test the hypothesis that activation of the epithelial 5-HT4
receptor attenuates the development of colitis, and improves recovery from established
colitis. Our findings demonstrate that treatment with the 5-HT4 agonist, tegaserod,
59

protects the colon in both of these ways. Treatment with the 5-HT4 agonist significantly
reduced DAI and HDS in two different, commonly used models of colitis, indicating an
anti-inflammatory effect. Evidence reported here indicates that epithelial 5-HT4 receptor
stimulation can exert its protective effects through several mechanisms, including
increased epithelial proliferation, enhanced epithelial cell migration, and resistance to
oxidative stress-induced apoptosis. Furthermore, treatment with the 5-HT4 agonist
attenuated inflammation-induced changes in colonic propulsive motility resulting in
healthy motility patterns. All of these effects were blocked by the 5-HT4 antagonist,
GR113808. Importantly, data reported here also suggest that epithelial 5-HT4 receptors
play an important physiological role in maintaining mucosal integrity since inhibition of
this receptor in normal animals leads to an inflammatory state and disrupted motility
patterns. Collectively, these studies contribute new knowledge regarding the protective
actions of 5-HT4 receptor activation, and evidence for an anti-inflammatory role of 5-HT4
in normal physiology.
Serotonin and colitis
Prior to the current investigation, which supports an anti-inflammatory role of 5-HT
signaling in the mucosa, it had been established that 5-HT can exert a pro-inflammatory
influence (Gershon, 2012). Data in support of the pro-inflammatory role of 5-HT in
colitis include the findings that mice lacking or deficient in mucosal 5-HT develop less
severe colitis (Ghia et al., 2009), and SERT KO mice develop more severe colitis
(Bischoff et al., 2009), than control animals. In further studies to discern the mechanisms
responsible for this pro-inflammatory action of 5-HT, Kahn and colleagues demonstrated
that this effect is likely mediated by activation of 5-HT7 receptors on dendritic cells in the
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lamina propria (Li et al., 2011; Kim et al., 2013). These findings show that 5-HT made in
the mucosa is a major player in the development of inflammation in animal models of
colitis. However, these previous studies examined the global effect of gut-derived 5-HT
on inflammation. The current study specifically examined the role of the 5-HT4 receptor
in the context of inflammation since previous work in our lab would suggest that
activation of epithelial 5-HT4 receptors may be protective (Hoffman et al., 2012).
In addition to the protective, anti-inflammatory effect of epithelial 5-HT4 receptor
stimulation reported here, there is evidence that 5-HT4 receptors play a protective,
neurogenic effect in the muscularis. Activation of 5-HT4 receptors in primary cultures of
enteric neurons promotes neuronal growth and survival, and in vivo, agonist treatment
promotes neurogenesis in adult mice (Liu et al., 2009). These findings are supported and
extended by the studies of Takaki and colleagues demonstrating that recovery of the
recto-anal reflex is significantly augmented, through neurogenesis and axon outgrowth,
by 5-HT4 receptor treatment following rectal transection and anastomosis (Matsuyoshi et
al., 2010; Kawahara et al., 2012; Takaki et al., 2014). Furthermore, in in vivo models of
colitis, which is a state of increased bioavailable 5-HT (Mawe and Hoffman, 2013), there
is 5-HT4 receptor mediated enteric neurogenesis (Belkind-Gerson et al., 2015). Taken
together with the results reported here, it is clear that the 5-HT4 receptor exerts protective
actions in the inner and outer layers of the gut.
Mechanisms
Based on the findings reported here, several mechanisms contribute to the protective
effects of epithelial 5-HT4 receptor stimulation, and these mechanisms are apparently
effective for both Th1- (TNBS) and Th2-predominant (DSS) inflammatory responses.
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One way that 5-HT4 receptor stimulation is acting is through increased barrier function.
We found that administration of tegaserod increased both cell proliferation and epithelial
cell migration, and that these effects were blocked by a 5-HT4 antagonist. It is known
that in animal models of colitis and in IBD, the epithelial barrier is considered “leaky”
and unable to effectively block luminal pathogens from further infecting and inflaming
the host (Berkes et al., 2003; Turner, 2009; Fasano, 2011; Teshima et al., 2012).
Furthermore, in DSS colitis, there is a reduction in cell proliferation and an increase in
apoptosis, also likely contributing to reduced barrier function (Araki et al., 2010). It is
possible that activation of 5-HT4 receptors in inflamed tissue stimulates cell proliferation,
and with more cells, more coverage for open or wounded areas. It is also likely that
activation of 5-HT4 receptors stimulates cell migration in the short term to mitigate the
damage by covering the areas in which epithelial erosion has occurred. Both of these
mechanisms are known to be downstream of tumor necrosis factor-alpha (TNF-α) which
is expressed during inflammation, and these pro-survival mechanisms could be
upregulated further with 5-HT4 receptor stimulation to promote cell survival and
proliferation (Leppkes et al., 2014).
5-HT4 receptor activation could also exert its protective effect in these models
through resistance to apoptosis due to oxidative stress with 5-HT4 receptor activation.
Oxidative stress is a key feature of inflammation and has been noted in both DSS and
TNBS colitis (Shi et al., 2011), often initiating cell death. Treatment with a 5-HT4
agonist rendered CaCo-2 cells resistant to cell loss caused by the free radical donor H2O2,
in a 5-HT4 antagonist-sensitive manner.
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Another mechanism that likely contributes to the protective effect of 5-HT4
receptor stimulation is the secretion of mucus from goblet cells. The mucus layer serves
as a protective barrier, and it is thought to be protective since disruption of this barrier
with mucolytic agents or deletion of the MUC2 gene results in colitis (Van der Sluis et
al., 2006; Johansson et al., 2013). Goblet cells express the 5-HT4 receptor, and 5-HT4
receptor activation leads to degranulation (Hoffman et al., 2012).
Colonic motility
The guinea pig distal colon ex vivo model of motility is probably the most extensively
characterized animal model of propulsive motility (Costa and Furness, 1976; D'Antona et
al., 2001; Hoffman et al., 2010). We have previously used this assay to investigate
changes in motility that are associated with TNBS colitis (Linden et al., 2003b; Strong et
al., 2010), and we have linked disruptions in motility to inflammation-induce
neuroplasticity, particularly intrinsic primary afferent neuron hyperexcitability (Hoffman
et al., 2011) and attenuated purinergic neuromuscular transmission (Roberts et al., 2013).
In the current study we found that that treatment of TNBS-inflamed guinea pigs with the
5-HT4 agonist protected or restored colonic motility and motility patterns. Consistent
with our previous report linking disrupted motility to attenuation of the IJP (Roberts et
al., 2013), the amplitude of the IJP is comparable to that of control animals following 5HT4 agonist treatment in TNBS colitis animals.
The 5-HT4 Receptor Plays a Physiological Role in Maintaining Epithelial Integrity
Data from studies reported here involving various models and paradigms of 5-HT4
receptor stimulation in colitis indicated that this receptor plays a host defense role in
inflammatory conditions and that this process involves a number of actions that support
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the epithelial barrier and resistance to damage from oxidative stress. This novel
information led to the question of whether 5-HT4 receptor activity exerts a protective
influence in the mucosal layer under normal physiological conditions. It stands to reason
that endogenous 5-HT may be acting on epithelial 5-HT4 receptors to dampen
physiological inflammation and maintain homeostasis. Treatment with the antagonist,
GR113808, inhibited these normal physiological functions and resulted in evidence of
inflammation, despite a lack of colonic insult (DSS or TNBS). We observed the
development of DAI, HDS, bacterial translocation, and reduction in cell proliferation in
normal mice treated with a 5-HT4 antagonist. Furthermore, inhibition of 5-HT4 receptors
in the colonic epithelium of normal guinea pigs resulted in the appearance of obstructed
motility patterns, which is not a feature of healthy colons. Consistent with these results,
there were situations in our colitis paradigms in which antagonist treatment not only
blocked the agonist, but led to a condition that was worse than the vehicle treated
inflamed group. This included the histological damage in the DSS mouse colitis
prevention paradigm (Fig. 1) as well as the obstructed motility pattern in guinea pigs with
TNBS colitis (Fig. 7).
With regard to the harmful effects of 5-HT4 antagonist treatment on the colon, it is yet
unclear whether the antagonist is blocking the effects of 5-HT released from nearby
enterochromaffin cells, or if the treatment is dampening potential constitutive activity of
the receptor on epithelial cells. Certain isoforms of the 5-HT4 receptor have low level
constitutive activity which could lead to a steady state activation of the protective
pathways that are stimulated by 5-HT4 receptor activation with an agonist (Blondel et al.,
1998; Claeysen et al., 2000; Claeysen et al., 2001). The antagonist that was used in the
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current studies, GR113808, can suppress this constitutive activity by acting as an inverse
agonist (Kamel et al., 2005).
Concluding remarks
Novel concepts have emerged from this study that could provide a new and safe
treatment strategy for the treatment of colitis, and expand our appreciation of the roles of
5-HT receptor signaling in the GI tract. Here we report the discovery of a protective and
healing action of epithelial 5-HT4 receptor stimulation in the colon. Treatment in two
different models of colitis decreased the extent of inflammation as it was occurring, and
accelerated the process of remission once colitis had been established. This beneficial
effect likely involves several mechanisms that include enhanced barrier function and
resistance to oxidative stress, and treatment with 5-HT4 agonist led to an improvement in
colonic motor function. Thus these findings demonstrate that luminally restricted, and
therefore low risk, administration of 5-HT4 agonists could be beneficial in the treatment
of IBD. The discovery that 5-HT4 receptors also contribute to the epithelial fitness in
healthy animals reveals a new role for 5-HT signaling in the mucosal layer, and one that
physiologically opposes the previously identified pro-inflammatory actions of 5-HT in
the colon. Collectively, these findings advance our understanding of colonic physiology
and pathophysiology, and provide a new target for the treatment of colonic inflammation.

65

WORKS CITED
Araki Y, Mukaisyo K, Sugihara H, Fujiyama Y, Hattori T (2010) Increased apoptosis and
decreased proliferation of colonic epithelium in dextran sulfate sodium-induced
colitis in mice. Oncology reports 24:869-874.
Becker C, Watson AJ, Neurath MF (2013) Complex roles of caspases in the pathogenesis
of inflammatory bowel disease. Gastroenterology 144:283-293.
Belkind-Gerson J, Hotta R, Nagy N, Thomas AR, Graham H, Cheng L, Solorzano J,
Nguyen D, Kamionek M, Dietrich J, Cherayil BJ, Goldstein AM (2015) Colitis
Induces Enteric Neurogenesis Through a 5-HT4-dependent Mechanism.
Inflammatory bowel diseases 21:870-878.
Berger M, Gray JA, Roth BL (2009) The expanded biology of serotonin. Annual review
of medicine 60:355-366.
Berkes J, Viswanathan VK, Savkovic SD, Hecht G (2003) Intestinal epithelial responses
to enteric pathogens: effects on the tight junction barrier, ion transport, and
inflammation. Gut 52:439-451.
Bischoff SC, Mailer R, Pabst O, Weier G, Sedlik W, Li Z, Chen JJ, Murphy DL, Gershon
MD (2009) Role of serotonin in intestinal inflammation: knockout of serotonin
reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in
mice. American journal of physiology Gastrointestinal and liver physiology
296:G685-695.
Blondel O, Gastineau M, Langlois M, Fischmeister R (1998) The 5-HT4 receptor
antagonist ML10375 inhibits the constitutive activity of human 5-HT4(c)
receptor. British journal of pharmacology 125:595-597.
Bockaert J, Claeysen S, Compan V, Dumuis A (2008) 5-HT(4) receptors: history,
molecular pharmacology and brain functions. Neuropharmacology 55:922-931.
Brierley SM, Linden DR (2014) Neuroplasticity and dysfunction after gastrointestinal
inflammation. Nature reviews Gastroenterology & hepatology 11:611-627.
Bulbring E, Crema A (1958) Observations concerning the action of 5-hydroxytryptamine
on the peristaltic reflex. British journal of pharmacology and chemotherapy
13:444-457.
Bulbring E, Lin RC (1958) The effect of intraluminal application of 5-hydroxytryptamine
and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its
66

release in relation to intraluminal pressure and propulsive activity. The Journal of
physiology 140:381-407.
Claeysen S, Sebben M, Becamel C, Parmentier ML, Dumuis A, Bockaert J (2001)
Constitutively active mutants of 5-HT4 receptors are they in unique active states?
EMBO reports 2:61-67.
Claeysen S, Sebben M, Becamel C, Eglen RM, Clark RD, Bockaert J, Dumuis A (2000)
Pharmacological properties of 5-Hydroxytryptamine(4) receptor antagonists on
constitutively active wild-type and mutated receptors. Molecular pharmacology
58:136-144.
Clement MV, Ponton A, Pervaiz S (1998) Apoptosis induced by hydrogen peroxide is
mediated by decreased superoxide anion concentration and reduction of
intracellular milieu. FEBS Lett 440:13-18.
Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of
dextran sulfate sodium experimental murine colitis. Laboratory investigation; a
journal of technical methods and pathology 69:238-249.
Costa M, Furness JB (1976) The peristaltic reflex: an analysis of the nerve pathways and
their pharmacology. Naunyn-Schmiedeberg's archives of pharmacology 294:4760.
D'Antona G, Hennig GW, Costa M, Humphreys CM, Brookes SJ (2001) Analysis of
motor patterns in the isolated guinea-pig large intestine by spatio-temporal maps.
Neurogastroenterology and motility : the official journal of the European
Gastrointestinal Motility Society 13:483-492.
Deitch EA, Kemper AC, Specian RD, Berg RD (1992) A study of the relationship among
survival, gut-origin sepsis, and bacterial translocation in a model of systemic
inflammation. The Journal of trauma 32:141-147.
Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of
inflammatory bowel disease. Gastroenterology 109:1344-1367.
Fasano A (2011) Zonulin and its regulation of intestinal barrier function: the biological
door to inflammation, autoimmunity, and cancer. Physiological reviews 91:151175.
Fujisawa M, Murata T, Hori M, Ozaki H (2010) The 5-HT4 receptor agonist mosapride
attenuates NSAID-induced gastric mucosal damage. Journal of gastroenterology
45:179-186.

67

Gaudio E, Taddei G, Vetuschi A, Sferra R, Frieri G, Ricciardi G, Caprilli R (1999)
Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and
ultrastructural aspects. Digestive diseases and sciences 44:1458-1475.
Gershon MD (2012) Serotonin is a sword and a shield of the bowel: serotonin plays
offense and defense. Transactions of the American Clinical and Climatological
Association 123:268-280; discussion 280.
Ghia JE, Li N, Wang H, Collins M, Deng Y, El-Sharkawy RT, Cote F, Mallet J, Khan WI
(2009) Serotonin has a key role in pathogenesis of experimental colitis.
Gastroenterology 137:1649-1660.
Heath JP (1996) Epithelial cell migration in the intestine. Cell biology international
20:139-146.
Hoffman JM, Brooks EM, Mawe GM (2010) Gastrointestinal Motility Monitor (GIMM).
Journal of visualized experiments : JoVE.
Hoffman JM, McKnight ND, Sharkey KA, Mawe GM (2011) The relationship between
inflammation-induced neuronal excitability and disrupted motor activity in the
guinea pig distal colon. Neurogastroenterology and motility : the official journal
of the European Gastrointestinal Motility Society 23:673-e279.
Hoffman JM, Tyler K, MacEachern SJ, Balemba OB, Johnson AC, Brooks EM, Zhao H,
Swain GM, Moses PL, Galligan JJ, Sharkey KA, Greenwood-Van Meerveld B,
Mawe GM (2012) Activation of colonic mucosal 5-HT(4) receptors accelerates
propulsive motility and inhibits visceral hypersensitivity. Gastroenterology
142:844-854 e844.
Johansson ME, Gustafsson JK, Holmen-Larsson J, Jabbar KS, Xia L, Xu H, Ghishan FK,
Carvalho FA, Gewirtz AT, Sjovall H, Hansson GC (2013) Bacteria penetrate the
normally impenetrable inner colon mucus layer in both murine colitis models and
patients with ulcerative colitis. Gut.
Joly F, Mayeur C, Messing B, Lavergne-Slove A, Cazals-Hatem D, Noordine ML,
Cherbuy C, Duee PH, Thomas M (2009) Morphological adaptation with
preserved proliferation/transporter content in the colon of patients with short
bowel syndrome. American journal of physiology Gastrointestinal and liver
physiology 297:G116-123.
Kamel R, Eftekhari P, Garcia S, Berthouze M, Berque-Bestel I, Peter JC, Lezoualc'h F,
Hoebeke J (2005) A high-affinity monoclonal antibody with functional activity
against the 5-hydroxytryptaminergic (5-HT4) receptor. Biochemical
pharmacology 70:1009-1018.
68

Kawahara I, Kuniyasu H, Matsuyoshi H, Goto K, Obata K, Misawa H, Fujii H, Takaki M
(2012) Comparison of effects of a selective 5-HT reuptake inhibitor versus a 5HT4 receptor agonist on in vivo neurogenesis at the rectal anastomosis in rats.
American journal of physiology Gastrointestinal and liver physiology 302:G588597.
Keating C, Beyak M, Foley S, Singh G, Marsden C, Spiller R, Grundy D (2008) Afferent
hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of
altered serotonin metabolism. The Journal of physiology 586:4517-4530.
Kim JJ, Bridle BW, Ghia JE, Wang H, Syed SN, Manocha MM, Rengasamy P, Shajib
MS, Wan Y, Hedlund PB, Khan WI (2013) Targeted inhibition of serotonin type
7 (5-HT7) receptor function modulates immune responses and reduces the
severity of intestinal inflammation. Journal of immunology (Baltimore, Md :
1950) 190:4795-4804.
Leppkes M, Roulis M, Neurath MF, Kollias G, Becker C (2014) Pleiotropic functions of
TNF-alpha in the regulation of the intestinal epithelial response to inflammation.
International immunology 26:509-515.
Leung E, Blissard D, Jett MF, Eglen RM (1995) Investigation of the 5hydroxytryptamine receptor mediating the "transient" short-circuit current
response in guinea-pig ileal mucosa. Naunyn-Schmiedeberg's archives of
pharmacology 351:596-602.
Li N, Ghia JE, Wang H, McClemens J, Cote F, Suehiro Y, Mallet J, Khan WI (2011)
Serotonin activates dendritic cell function in the context of gut inflammation. The
American journal of pathology 178:662-671.
Linden DR, Sharkey KA, Mawe GM (2003a) Enhanced excitability of myenteric AH
neurones in the inflamed guinea-pig distal colon. The Journal of physiology
547:589-601.
Linden DR, Sharkey KA, Ho W, Mawe GM (2004) Cyclooxygenase-2 contributes to
dysmotility and enhanced excitability of myenteric AH neurones in the inflamed
guinea pig distal colon. The Journal of physiology 557:191-205.
Linden DR, Chen JX, Gershon MD, Sharkey KA, Mawe GM (2003b) Serotonin
availability is increased in mucosa of guinea pigs with TNBS-induced colitis.
American journal of physiology Gastrointestinal and liver physiology 285:G207216.
Liu MT, Kuan YH, Wang J, Hen R, Gershon MD (2009) 5-HT4 receptor-mediated
neuroprotection and neurogenesis in the enteric nervous system of adult mice. The
69

Journal of neuroscience : the official journal of the Society for Neuroscience
29:9683-9699.
MacEachern SJ, Patel BA, Keenan CM, Dicay M, Chapman K, McCafferty DM, Savidge
TC, Beck PL, MacNaughton WK, Sharkey KA (2015) Inhibiting Inducible Nitric
Oxide Synthase in Enteric Glia Restores Electrogenic Ion Transport in Mice With
Colitis. Gastroenterology 149:445-455 e443.
Matsuyoshi H, Kuniyasu H, Okumura M, Misawa H, Katsui R, Zhang GX, Obata K,
Takaki M (2010) A 5-HT(4)-receptor activation-induced neural plasticity
enhances in vivo reconstructs of enteric nerve circuit insult.
Neurogastroenterology and motility : the official journal of the European
Gastrointestinal Motility Society 22:806-813, e226.
Mawe GM, Hoffman JM (2013) Serotonin signalling in the gut--functions, dysfunctions
and therapeutic targets. Nature reviews Gastroenterology & hepatology 10:473486.
Nichols DE, Nichols CD (2008) Serotonin receptors. Chemical reviews 108:1614-1641.
Novak EA, Mollen KP (2015) Mitochondrial dysfunction in inflammatory bowel disease.
Frontiers in cell and developmental biology 3:62.
Reddy SN, Bazzocchi G, Chan S, Akashi K, Villanueva-Meyer J, Yanni G, Mena I,
Snape WJ, Jr. (1991) Colonic motility and transit in health and ulcerative colitis.
Gastroenterology 101:1289-1297.
Roberts JA, Durnin L, Sharkey KA, Mutafova-Yambolieva VN, Mawe GM (2013)
Oxidative stress disrupts purinergic neuromuscular transmission in the inflamed
colon. The Journal of physiology 591:3725-3737.
Shi XZ, Winston JH, Sarna SK (2011) Differential immune and genetic responses in rat
models of Crohn's colitis and ulcerative colitis. American journal of physiology
Gastrointestinal and liver physiology 300:G41-51.
Strober W, Fuss IJ, Blumberg RS (2002) The immunology of mucosal models of
inflammation. Annual review of immunology 20:495-549.
Strong DS, Cornbrooks CF, Roberts JA, Hoffman JM, Sharkey KA, Mawe GM (2010)
Purinergic neuromuscular transmission is selectively attenuated in ulcerated
regions of inflamed guinea pig distal colon. The Journal of physiology 588:847859.
Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, Meddings JB, Abraham C, Turner
JR (2009) Targeted epithelial tight junction dysfunction causes immune activation
70

and contributes to development of experimental colitis. Gastroenterology
136:551-563.
Takaki M, Goto K, Kawahara I (2014) The 5-hydroxytryptamine 4 Receptor Agonistinduced Actions and Enteric Neurogenesis in the Gut. Journal of
neurogastroenterology and motility 20:17-30.
Teshima CW, Dieleman LA, Meddings JB (2012) Abnormal intestinal permeability in
Crohn's disease pathogenesis. Annals of the New York Academy of Sciences
1258:159-165.
Turner JR (2009) Intestinal mucosal barrier function in health and disease. Nature
reviews Immunology 9:799-809.
Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van
Goudoever JB, Buller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AW
(2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2
is critical for colonic protection. Gastroenterology 131:117-129.
Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity
screening. Nature protocols 1:1112-1116.
Villanacci V, Antonelli E, Geboes K, Casella G, Bassotti G (2013) Histological healing
in inflammatory bowel disease: a still unfulfilled promise. World journal of
gastroenterology : WJG 19:968-978.

71

A

DSS-inflamed

250 µm

DSS/5HT4 Agonist

Disease Activity Index

*

Score

10

4

Vehicle

****

***

5

0

Agonist Antag/Agonist

Vehicle

Agonist Antag/Agonist

Vehicle

Agonist Antag/Agonist

8

10

*

8

*

6

Score

6
4

4
2

2
0

**

15

2

Score

TNBS Colitis

*

6

0

C

Histological Damage Score

8

Score

DSS Colitis

B

DSS/Agonist + Antagonist

Vehicle

Agonist Antag/Agonist

Figure 1

72

0

Figure Legend
Figure 1. Daily intraluminal treatment with the 5-HT4 agonist, tegaserod (1mg/Kg)
reduced the extent of DSS and TNBS colitis. A. Micrographs illustrating typical
histological features in colons from the treatment groups. B. In DSS colitis, the 5-HT4
receptor agonist significantly reduced the DAI and HDS, and this effect was reversed by
antagonist treatment (1 mg/Kg) (vehicle, n=9; agonist, n=10; antagonist, n=5). C. In
TNBS colitis, agonist treatment significantly reduced the DAI, but did not affect the HDS
(n=7 for all groups). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 by one-way
ANOVA.
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Figure 2. Daily intraluminal treatment with the 5-HT4 agonist, tegaserod (1mg/Kg)
beginning on day 6, after colitis had been established, accelerated recovery from DSS and
TNBS colitis. A. In DSS colitis, the 5-HT4 receptor agonist significantly improved the
DAI by day 12, and at the termination of the experiment on day 15, both the DIA and
HDS were significantly improved as compared to the vehicle control and antagonist plus
agonist treatment groups. (vehicle, n=21; agonist, n=23; antagonist, n=5). B. In TNBS
colitis, significant improvement in the DIA was detected on Day 9, and at the day 15 time
point. Both the DIA and HDS were significantly improved as compared to vehicle
control and the antagonist plus agonist groups (vehicle, n=13; agonist, n=14; antagonist,
n=5). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 by two-way ANOVA for DIA and
one way-ANOVA for HDS. In the DIA graphs, comparisons were made between agonist
treatment and the other groups.
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Figure 3. Unlike intraluminal administration, intraperitoneal administration of tegaserod
for 7 days does not exert a protective effect. Graphs illustrate the lack of an effect of the
5-HT4 agonist on DAI or HDS in animals with DSS colitis and treated with tegaserod by
intraperitoneal injection (1 mg/Kg) beginning on day 6. (vehicle, n=7; agonist, n=8)
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Figure 4. Intraluminal treatment with tegaserod increased epithelial proliferation. A.
Graph demonstrating the proportion of crypt epithelial cells that were immunoreactive for
the proliferation marker, Ki-67 (vehicle, n=10; agonist, n=9; antagonist, n=9). B.
Representative photomicrographs demonstrating Ki67 immunoreactivity (red) and DAPI
counterstaining (green). *p<0.05; **p<0.01 by one-way ANOVA.
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Figure Legend
Figure 5. Treatment of CaCo-2 cells with tegaserod elicited an increase in the rate of cell
migration, and increased resistance to cell loss due to oxidative stress. A. Graph
illustrating closure of scratches in CaCo-2 monolayer cultures due to cellular migration
after 48 hr (6 wells per treatment group, 2 scratches per well). B. Graph showing CaCo-2
cell survival data from cultures that were treated with normal medium (control) or 200
µM H2O2 (n=4 experiments). C. Photomicrographs of CaCo-2 cultures showing
scratches at the 0 and 48 hr time points. ). **p<0.01, ****p<0.0001 by one-way
ANOVA.
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Figure Legend
Figure 6. Daily intraluminal treatment with tegaserod (1 mg/Kg) improved distal colon
propulsive motility in guinea pigs with TNBS colitis. A. Graph illustrating rate of pellet
propulsion along the length of the colon (control, n=6; TNBS/vehicle, n=9;
TNBS/agonist, n=6; TNBS/agonist plus antagonist, n=4; ****p<0.0001, one-way
ANOVA). B. Graph showing the proportion of trials in which the fecal pellet cleared the
colon or was obstructed, and did not clear the colon within 5 min (data based on 5-6 trials
per animal; ***p<0.001, ****p<0.0001, Fisher’s Exact Test).
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Figure Legend
Figure 7. Purinergic inhibitory neuromuscular transmission was significantly improved
by daily intraluminal treatment with tegaserod (1 mg/Kg). Graph demonstrating the
amplitudes of inhibitory junction potential in the circular muscle of the guinea pig.
(Control, n=12 events from 3 colons; TNBS/vehicle, n=42 events from 8 colons;
TNBS/agonist, n=42 events from 8 colons. ****p<0.0001 by one-way ANOVA)
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Figure 8. Intraluminal administration of the 5-HT4 antagonist GR113808 (1 mg/Kg)
induced colitis in mice. A. Micrographs illustrating typical histological features in
colons from mice treated with a vehicle or with the antagonist. Note the lymphocytic
infiltration and the crypt disruption in the antagonist treatment. B. Antagonist treatment
resulted in a significant increase in the DAI that was detected as early as day 3, and an
increase in the HDS. n=10/group. **p<0.01; ****p<0.0001 by two-way ANOVA for
DIA and by t-test for HDS.
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Figure Legend
Figure 9. Daily intraluminal administration of the 5-HT4 antagonist GR113808 (1
mg/Kg) disrupted barrier function in mice. A. Graph demonstrating that the proportion
of crypt epithelial cells that were immunoreactive for the proliferation marker, Ki-67 was
significantly decreased in animals treated with the antagonist (vehicle, n=8; antagonist,
n=10; ****p<0.001 by t-test). B. Graph demonstrating the proportion of mice in which
bacteria were detected in the liver or spleen following 10 days of vehicle or antagonist
treatment. Vehicle, n=5; antagonist, n=3; ****p<0.0001, Fisher’s Exact Test.
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Figure Legend
Figure 10. Daily intraluminal administration of a 5-HT4 antagonist in guinea pigs
resulted in a disruption of propulsive motility. The graph illustrates the proportion of
trials in which pellet propulsion was obstructed for at least 5 min. Vehicle, n=31 trials
from 4 colons; antagonist, n=30 trials from 5 colons; ****p<0.0001, Fisher’s Exact Test.
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CHAPTER 3: FINAL CONCLUSIONS AND FUTURE DIRECTIONS
I. Implications of epithelial 5-HT4 receptor agonists in colitis
A. Summary and Conclusions
Inflammatory bowel disease (IBD) is chronic inflammation of the gastrointestinal
tract, and is often accompanied by symptoms such as severe diarrhea or constipation,
pain, and weight loss (Baumgart and Sandborn, 2012; Ordas et al., 2012). Furthermore,
patients with IBD are at risk of inflammation-induced complications such as stenosis and
fistula formation, bowel obstruction, and ulcers. Current therapies include
aminosalicylates, corticosteroids, immunomodulators, antibiotics and biological
therapies. Steroids and antibiotics are not recommended for long-term use, and for many
patients, these other therapies are inadequate or lose effectiveness over time. Treatment
for IBD has two main goals: 1) to recover from symptoms and 2) to maintain remission
and prevent new flares. The Crohn’s and Colitis Foundation of America even states that
a global priority for research is to define cell types and pathways associated with gut
stability versus inflammation, with the ultimate goal of finding new targeted therapies.
This dissertation examines a novel target for the treatment of IBD that addresses these
two goals, as well as new understanding of one serotonin receptor, 5-HT4, that may serve
an anti-inflammatory role in normal physiology.
Results from my dissertation studies show that activation of 5-HT4 receptors in the
colonic epithelium attenuates the development of inflammation in animal models of
colitis and accelerates the recovery from established colitis. Furthermore, agonist
treatment increases cell proliferation, improves wound healing, and protects against
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oxidative stress induced apoptosis. In functional studies, agonist treatment attenuated the
dysmotility observed in TNBS colitis, likely through restoration or reversal of the
changes that neurons undergo in response to inflammation.
B. Alternative Approaches and Future Directions
1. Anti-inflammatory Actions of 5-HT4 Receptor Agonists
IBD’s hallmark characteristic is inflammation of the colon, and our models of colitis
mimic some of the distinguishing features between the two most common forms of IBD,
Crohn’s Disease and Ulcerative Colitis. The disease activity index (DAI) is a widely
used measure that takes into account weight loss, stool consistency, and presence of
blood in the feces (Cooper et al., 1993). This is a useful tool that essentially is a noninvasive “snapshot” of symptoms that can be tracked over time, similar to what IBD
patients might report to their doctors.
Using the DAI, we were able to show that mice treated with the 5-HT4 receptor
agonist daily during the induction of both DSS and TNBS colitis showed attenuated
symptoms. This finding is relevant because it could mimic what happens during the
onset of an inflammatory “flare”. If taking a 5-HT4 receptor agonist could reduce the
severity of flares, IBD patients could potentially require lower or less frequent doses of
the aggressive medications used to treat acute flares, such as steroids and antibiotics.
Additionally, treatment with the 5-HT4 receptor agonist also accelerated recovery
from established colitis in both models. For many IBD patients, flares seriously disrupt
their lives, resulting in loss of productivity and quality of life. Treatment with the agonist
significantly improved symptoms sooner. Not only would reducing recovery time benefit
quality of life and productivity for IBD patients, but it is also likely that by bringing the
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patients into remission sooner, they can avoid some of the long-term consequences of
low-grade inflammation.
The gold standard approach for the assessment of inflammation in colitis is histology.
For many patients an endoscopy or colonoscopy is used to perform a macroscopic
examination for the presence of inflammation, but it has been reported that histological
healing and endoscopic evidence of mucosal healing do not correlate well (Villanacci et
al., 2013), and that histological evaluation may be a better predictor of healing and
continued remission (Marchal Bressenot et al., 2015). Fortunately, it is possible to
remove colonic tissue from the colitis animal models and look at the histological features
to gain a better understanding of the inflammation using hematoxylin and eosin (H&E).
Examining the H&E stained sections, we can observe epithelial integrity, crypt
architecture, presence of monocytes, lymphocytes and polymorphonuclear cells in the
lamina propria, as well as microscopic evidence of erosions or ulcers. These features are
not obvious to the naked eye, but give a very clear picture of inflammation. A trained
pathologist helped me identify key characteristics of inflammation and together we
created a scoring rubric for histological damage scores (HDS) based on a variety of
histological grading scales (Geboes et al., 2000; Burich et al., 2001), for use with H&E
sections.
Although there was a significant indication of reduced inflammation in the DSS
prevention model, there was robust evidence of improved histology in the recovery
paradigms for both DSS and TNBS. These findings are very exciting, because they
indicate that epithelial 5-HT4 receptor activation actually reduces inflammation, rather
than just relieving the symptoms. Using histological evidence of mucosal healing as a
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therapy endpoint, patients might remain on therapies until actual healing has occurred,
and thus, may remain in remission longer.
Although these studies have obvious clinical relevance, they are not without
limitations. Inflammation is a complex and dynamic process with many signaling
molecules, most of which can be measured. Many researchers perform assays showing
changes in common pro-inflammatory (IL-6, TNF-alpha) or anti-inflammatory (IL-10,
TGF-beta) cytokines. While we tried to quantify changes in these cytokines using qPCR, we were unable to detect significant differences. It is possible that due to the
timing of the paradigms we missed when these differences were most pronounced.
Particularly, in the recovery paradigm, many of the inflammatory markers would be near
control as inflammation had shifted from acute to more low-grade chronic. Improved
approaches to reveal possible differences in cytokine levels would be to increase the
number of time points, or to increase our search by using a cytokine panel, such as a
Luminex 25-plex. Unfortunately, these types of assays can be very cost prohibitive,
especially in light of the lack of significant findings using qPCR. Another common way
to assess inflammation is by measuring myeloperoxidase (MPO). The MPO assay is an
approximate measure of neutrophils, macrophages, and polymorphonuclear cells, which
are increased in inflammation. We initially tried this technique, but failed to detect
consistent or significant results.
2. Improved Wound Healing with 5-HT4 Receptor Activation
One of the major pathological features of IBD is the presence of mucosal erosions
and ulcers. These areas are bare of the typical columnar epithelium that acts as a physical
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barrier between the luminal contents and the rest of the body. Without this level of
protection, luminal pathogens can invade and cause infection and further inflammation.
To restore the epithelium, there are three main processes: 1) migration, 2) proliferation,
and 3) differentiation (Sturm and Dignass, 2008). In the initial repair phase after tissue
insult, adjacent cells flatten and migrate into the open area to fill in the damage (Heath,
1996). Once the area is covered, cells proliferate and differentiate to repopulate the
wounded area. While the process does occur in inflammation, accelerating this process
could reduce potential infection and further damage.
A commonly used in vitro model for wound healing is the scratch assay. In the
present studies, monolayers of CaCo-2 cells were grown to confluence and then a pipet
tip was dragged across the monolayer to simulate a wound. Early after the wound is
made, cells migrate and extend lamellipodia to fill in the space on the dish, and this can
be measured over time. The data from these studies show that activation of 5-HT4
receptors on these CaCo-2 cells increases cell migration into a scratch wound in a
monolayer. This increased migration is one potential mechanism by which activation of
epithelial 5-HT4 receptors reduces inflammation and accelerates recovery from colitis.
After the wound is primarily covered, adjacent cells begin to proliferate to more
adequately repair the wound. In the colon, the cells that are responsible for increased
proliferation are found in the basal third of the crypt. Crypt epithelial cells proliferate,
and differentiate as they migrate towards the lumen. The post-mitotic marker, Ki-67, is
commonly used to identify cells that have recently proliferated. The data from these
studies suggest that not only does epithelial 5-HT4 receptor activation increase cell
migration, but it also stimulates crypt epithelial cell proliferation, both of which
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contribute to closing the wound faster, and reducing the incidence of further
inflammation.
A third mechanism for the protective actions of epithelial 5-HT4 receptor activation in
colitis is reduced susceptibility to oxidative-stress induced apoptosis. Oxidative stress is
a known component of IBD and inflammation, potentially causing cell death. It has been
shown that in DSS colitis that there is a reduction in cell proliferation and increased
apoptosis (Araki et al., 2010). In cell culture, monolayers of CaCo-2 cells exposed to the
free radical donor, H2O2, undergo apoptosis. Treatment with the agonist reduced the
number cells that succumbed to apoptosis, suggesting increased resilience.
Collectively, our findings provide strong evidence that epithelial 5-HT4 receptor
activation improves wound healing through increased cell migration, increased cell
proliferation, and reduced oxidative stress-induced cell death. However, in vitro assays
were limited to CaCo-2 cells, which act as a population of enterocytes (Jumarie and
Malo, 1991). While this is a very common tool for studying the gastrointestinal
epithelium, it would be beneficial to expand to other culture models. Co-cultures of
different cell types found in the colonic epithelium could provide new evidence for the
interplay between cell types and their responses to 5-HT4 receptor stimulation. It is
reasonable to think that goblet cells secreting mucus in the presence of the agonist might
alter how enterocytes interact with the agonist. Another possible future direction is to
test the effects of 5-HT4 receptor activation in primary cultures from IBD patients. This
method might better direct personalized medicine.
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3. Barrier Function
It has been documented that the epithelial barrier is “leaky” in IBD and this is
recapitulated in animal models (Stein et al., 1998; Turner, 2009). These leaky barriers
show alterations in water flux into and out of the colon, and increased permeability to
luminal pathogens. Unfortunately, alterations in barrier function in the colon are not as
straightforward to measure in vivo.
We tried a number of methods to test for changes in barrier function between healthy
controls and inflamed animals. Without a change between controls and inflamed animals
under the experimental condition, we could not attempt to detect a meaningful change
with a 5-HT4 receptor agonist. Using Ussing chambers to measure FITC-dextran flux
from mucosal to serosal side we were able to show a moderate increase in flux in
inflamed tissue. However, because the range of FITC-flux in the inflamed animals was
so broad, with some being very leaky while others were not, the benefits of 5-HT4
receptor activation were not statistically significant.
Looking further for an alternative approach to test for changes in barrier function
associated with 5-HT4 receptor activation, we tested 5-HT4 receptor stimulation on CaCo2 cells to see if there were changes in tight junction protein transcript levels. Barrier
function is highly regulated by the tight junction proteins and is known to be disrupted in
inflammation (Forster, 2008). After stimulating CaCo-2 cells we did not detect a
significant change in transcript levels for occludin, ZO-1, or claudin family proteins,
which are tight junction proteins associated with increased barrier function. It would be
worthwhile to extend this study into colonic tissue from animal models, and even human
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biopsies to see if perhaps the cell line is not adequately representing changes in tight
junction proteins.
Finally, a very practical readout for barrier function is looking for bacterial
translocation from the lumen of the gut to the body, often the liver or spleen
(MacEachern et al., 2015). In health, gut bacteria should be unable to penetrate the
mucus and epithelial barrier, however, when the barriers are disrupted, bacterial
translocation is observed. While the previous methods of examining changes in barrier
function are valid and important, this assay is physiologically relevant as a readout. We
have preliminary data that suggests luminal 5-HT4 receptor activation during the
development of DSS colitis reduces bacterial translocation compared to vehicle treated
inflamed animals (Fig. 1). More experiments are needed to determine if this change is
significant, although one could argue that any reduction in bacterial translocation is a
meaningful difference.
4. Mucus
An often underappreciated, and very difficult to study, component of the gut defense
mechanisms involves the mucus layer. Mucus is the first line of defense against luminal
content and the quality of mucus is compromised in both animal models of colitis and
IBD patients (Johansson et al., 2013; Pelaseyed et al., 2014). Further evidence for the
importance of mucus in colitis is that mucin-2 (Muc-2) knockout mice spontaneously
develop colitis (Van der Sluis et al., 2006).
Due to the aqueous nature of mucus, normal fixation techniques do not preserve the
mucus layer as it is normally washed away. Other fixation techniques such as snap
freezing in pockets of other tissue, vapor fixation, and Carnoy’s fix which is non99

aqueous, are potential alternatives. Preliminary data from our lab had suggested that
acute 5-HT4 receptor stimulation of healthy ex vivo tissue preps caused goblet cell
cavitation, so we were interested in exploring that further. We have tried Carnoy’s
fixation followed by Periodic acid-Schiff’s and Alcian blue stain with varied success, we
have found that much of the gel mucus layer is still sloughed away and only fractions of
the adhered mucus layer remain. These fixation issues have prevented us from accurately
measuring changes in mucus.
Beyond fixation, there are other methods of measuring mucus. One in vivo method
requires exposing the colon and opening the gut tube to the mucosa. Carbon particles are
then applied to the mucosa and a micropipette is inserted into the mucus layer with a
micromanipulator. Mucus thickness is calculated by multiplying the sine of the angle of
insertion by the distance the pipette can be moved. This technique is more robust than
fixation, but it is not a protocol with which our lab has experience with.
We have sought alternative approaches to explore the role of mucus secretion under
5-HT4 receptor agonist treated conditions. Our recent approach has been to administer a
mucolytic agent (Qin et al., 2008), N-acetyl cysteine (NAC), shortly after treatment with
the agonist. We have preliminary data that suggest that epithelial 5-HT4 receptor
activation causes massive goblet cell degranulation and mucus secretion, and that followup treatment with NAC 10 minutes after agonist administration removes this secreted
mucus, leaving the colonic epithelium vulnerable. In our studies, 4 out of 10 animals
treated with NAC after tegaserod treatment did not survive the length of the study, while
only 1 NAC treatment after vehicle treatment did not survive (Fig. 2). This seems to be a
reasonable venue to pursue because it is a technique we can readily perform and it shows
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a physiological role for 5-HT4 receptor mediated mucus secretion. Another interesting
direction would be to use Muc2 knockout mice under similar experimental conditions to
this current study. This would allow us to tease apart the role of goblet cell 5-HT4
receptor activation and mucus secretion from the other protective roles of 5-HT4
receptors. However, a potential confounding issue with these mice is that they develop
colitis spontaneously.
5. Motility
A common complaint from IBD and IBS patients is altered GI motility. Previously,
5-HT4 receptor agonists have been used as pro-kinetic agents to alleviate the slowed
motility in constipation predominate IBS. Our lab has characterized neuroplasticity in
the TNBS-inflamed guinea pig distal colon, and we and others have shown that in TNBS
colitis there is disrupted motility. Treatment with 5-HT4 receptors were thought to work
on the myenteric nerve terminals to facilitate acetylcholine release and enhance tone. In
the GastroIntestinal Motility Monitor (GIMM) (Hoffman et al., 2010), an ex vivo organ
bath for the distal colon, bath application of 5-HT4 receptor agonists did not change
motility, but luminal application did. This led to the search for 5-HT4 receptors, and
ultimate discovery of, 5-HT4 receptors in the epithelium (Hoffman et al., 2012).
Using the GIMM, colonic propulsive motility can be measured as velocity and
motility clearance patterns can be determined. Propulsive motility is an important
readout because this is a physiologically relevant measure of bowel transit and function.
In TNBS guinea pigs, propulsive motility is greatly reduced, and this is attenuated to
healthy controls in agonist treated animals. Furthermore, the number of trials in which
the fecal pellet became obstructed is increased in vehicle treated TNBS guinea pigs,
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while treatment with the agonist prevented obstructions. This has major relevance to IBD
patients as the leading cause for surgery in both Crohn’s and ulcerative colitis is
obstruction.
There are a number of ways in which 5-HT4 receptor activation could be aiding in
motility, such as mucus secretion to reduce friction, improved wound healing to prevent
further inflammation, and restored water exchange. It is also known that in TNBS colitis
the dysfunction is due to reduced inhibitory junction potentials and hyperexcitable afterhyperpolarization (AH) neurons (Linden et al., 2003a; Strong et al., 2010). The current
study shows that treatment with the agonist attenuates this loss of inhibitory junction
potentials and restores it to healthy control levels. This is an important finding because
despite macroscopic and microscopic damage, there is a functional circuit that operates
typically. This would be a benefit to IBD patients because if treatment with the agonist
to the epithelium maintains normal enteric circuit function, they would likely have fewer
GI motility complaints or complications.
6. Visceral Sensitivity
Pain is one of the leading reasons for doctor’s visits in patients with IBD and IBS,
and current therapies are inadequate at treating it. Fortunately, there are a number of
models of rodent visceral nociception, and well-described methods for quantifying the
nociception (Greenwood-Van Meerveld et al., 2015). Animal models are a useful tool to
examine the underlying mechanisms of visceral sensitivity, as well as explore new
treatments options.
Previous studies from our lab and others have shown that in acute visceral
hypersensitivity, intraperitoneal, oral and intraluminal administration of 5-HT4 receptor
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agonists reduces responses to increasing intracolonic pressures in the typically
nociceptive range (Greenwood-Van Meerveld et al., 2006; Hoffman et al., 2012). To test
if epithelial 5-HT4 receptor agonists could improve visceral nociception in our models of
colitis, we recorded electromyographic (EMG) responses to differing colorectal
distensions (CRDs). We use CD-1 mice for this assay, even though rats are an easier
model for visceral nociception. We made this decision to keep our experiments
consistent, as switching between models can make comparisons difficult due to variance
in species and strains. We also decided to use TNBS colitis and the recovery model
because others have shown that there is persistent visceral hypersensitivity after TNBS
colitis (Greenwood-Van Meerveld et al., 2015). Unfortunately, in our model we were
unable to detect a post-inflammatory visceral hypersensitivity, and thus, we could not
show an effect of 5-HT4 receptor agonist treatment during recovery because there were
not significant differences between vehicle treated healthy mice and TNBS inflamed
mice. However, in our control groups, we did observe potentially significant changes in
normal nociception. Preliminary data demonstrate that antagonist treatment in noninflamed animals appears to increase nociception and sensitivity compared to agonist
treated non-inflamed animals (Fig. 3). Sensitivity can vary by species, mouse strain,
animal provider, and housing facilities, so there are many potential reasons for no
significant findings in our inflamed animals.
If we were to repeat this experiment, we would likely examine inflammation induced
visceral hypersensitivity before recovery begins. Although there is evidence of postinflammatory visceral hypersensitivity in other strains of mice, it appears that the CD-1
mice were resistant. We could look at visceral sensitivity during peak inflammation to
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see if the agonist treatment was attenuating nociception. Alternatively, we could move
the experiments into a strain of mice we know exhibits post-inflammatory visceral
hypersensitivity such as the C57BL/6 strain.

7. Therapies
Collectively, the results from this study support the pursuit of 5-HT4 receptor agonist
treatment to the epithelium as a therapeutic target, and we have provided evidence that in
the same concentrations, systemic administration is ineffective. One major concern that
has been voiced from clinicians when I present these data is that enema treatment in mice
may be effective at reaching most of the colon, but enema treatment in humans would
realistically only treat sigmoid and rectal disease. It is true that human enema may not be
the most effective treatment delivery for disease beyond the rectum, but there are other
ways of delivering a 5-HT4 receptor agonist to the colonic mucosa. One potential
delivery method would be to formulate a pH-sensitive tablet that releases the agonist
once it reaches the colon. Another potential delivery method uses new injectable or
consumable thermo-sensitive or pH-sensitive hydrogels for drug delivery (Bai et al.,
2015; Jhan et al., 2015). These hydrogels are liquid when the are delivered and form a
gel at body temperature or targeted pH, ensuring that the drug stays at the epithelium for
longer and can deliver drug locally. Another potential delivery mechanism is coated
intra-capsular pellets, which do not readily dissolve in the rest of the GI tract, causing
drug accumulation in the colon (Bose et al., 2014). Similarly, drug capsules can be
coated with a substrate that doesn’t dissolve in the GI tract, but that gets consumed by
colonic microflora, releasing the active drug to colonic tissue (Freire et al., 2010). All of
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these alternative methods for drug delivery do essentially what mouse enema treatment
does, which is deliver the drug to the target tissue with little absorption.

II. Implications of epithelial 5-HT4 receptors in normal physiology
A. Summary and Conclusions
In the periphery, 5-HT4 receptors have been described to be in alimentary tract,
urinary bladder, heart, and adrenal glands (Hegde and Eglen, 1996). In the gut, 5-HT3
and 5-HT4 receptors have become popular targets for addressing dysmotility and pain
experienced by IBD patients. However, while therapies target the 5-HT4 receptor, its role
in normal gut physiology is not well understood.
Previous work from our lab has shown that in healthy control tissue, application of 5HT4 receptor agonists causes 5-HT release from enterochromaffin (EC) cells, chloride
secretion from enterocytes, and mucus secretion from goblet cells (Hoffman et al., 2012),
but all of these actions were demonstrated with the addition of exogenous agonists, so the
question of whether these receptors are ever activated physiologically remained. Part of
this dissertation examined what physiological role those functions might have in vivo.
In these studies, it was initially observed that inflamed mice pretreated with the
antagonist had worse DAI and HDS indicating that the inhibition of the receptor leads to
inflammation. This led us to explore treatment with the 5-HT4 receptor agonist in noninflamed mice to see if basal 5-HT4 activity played a role in normal physiology and
health. Animals that were not treated with DSS or TNBS but given daily enemas of the
5-HT4 receptor antagonist, GR113808, showed evidence of inflammation by an
emergence and increase in DAI and HDS. Furthermore, we also saw an increase in
bacterial translocation, suggesting reduced barrier function. These data suggest that
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under normal physiological conditions, endogenous 5-HT acts on 5-HT4 receptors to
combat physiological inflammation.

B. Alternative approaches and future directions
1. Antagonists
In these studies we used the 5-HT4 receptor antagonist GR113808. It has also been
described as an inverse agonist, as there is likely low-level constitutive activity of the 5HT4 receptor normally (Claeysen et al., 2000; Kamel et al., 2005). In scenarios like this,
if a receptor has low-level constitutive activity normally, and then is blocked by an
inverse agonist, one would expect to see a reduction below baseline activity in the
readout measure. Based on this concept we believe that because we saw increased
inflammation in our colitis models when treated with GR113808, and because in noninflamed animals treated with the antagonist alone showed inflammation, that 5-HT4
receptor activation is anti-inflammatory.
In the future it would be beneficial to explore the use of other 5-HT4 receptor
antagonists to ensure that this effect is truly 5-HT4 receptor mediated. One study
examined 24 5-HT4 receptor antagonists and found that some antagonists are neutral
antagonists, some are partial agonists, and others are inverse agonists (Claeysen et al.,
2000). Additionally, it has been shown that 5-HT4 receptor splice variants and mutants
have differing levels of constitutive activity (Claeysen et al., 2001). Future experiments
should make use of CaCo-2 cells to study changes in constitutive 5-HT4 receptor activity.
Also, it will be important to more directly examine the physiological responses of normal
tissue to antagonist alone treatment.
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2. 5-HT4 Receptor Knockout Mice
All the previous studies were done in mice expressing the 5-HT4 receptor, and
manipulations of its function were made pharmacologically. Ideally, we would also like
to use the 5-HT4 receptor knockout mouse to confirm the effects we see with
pharmacological intervention. The 5-HT4 knockout mouse exists (Compan et al., 2004)
and we are currently beginning to breed animals to repeat the experiments performed in
these previous studies
It will be important to show that agonist treatment in the 5-HT4 KO mice does not
attenuate inflammation to further give evidence to the specific role of 5-HT4 receptors.
Furthermore, if we can demonstrate the knockouts do not benefit from the agonist, we
can transfect an adenoviral vector containing the 5-HT4 receptor into the colonic
epithelium by enema to see if it be can rescued. We hypothesize that transfection of 5HT4 receptors into the colonic epithelium will rescue the protective effects of the agonist
in knockout animals.
Additionally, the 5-HT4 KO mice will also help clear up any potential off target or
unanticipated protective effects of the agonist, tegaserod, used for most of the studies.
Tegaserod is a partial 5-HT4 receptor agonist, but it also can act on 5-HT2B receptors,
although with lower affinity. Unfortunately, the knockout mouse we have is a global
knockout and there are always concerns that there are compensatory mechanisms in these
mice. The Mayo Clinic, who provided our 5-HT4 knockouts, also has an inducible 5-HT4
mouse. If we could use this mouse model, we could allow the animal to develop
normally and then turn off 5-HT4 receptor expression. This is particularly advantageous
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for our experiments, as epithelial cells turn over rapidly, and expression could drop very
quickly, enabling us to determine the role of 5-HT4 receptors further.
III. Final Summary and Conclusions
The results of this dissertation suggest that epithelial 5-HT4 receptor activation
combats physiological inflammation, and their protective and anti-inflammatory
properties can be exploited for new therapeutics in IBD. The findings here are novel, as
they suggest an anti-inflammatory role for endogenous 5-HT.
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Figure 1
Treatment with N-acetyl cysteine (NAC) blocks the protective effects of tegaserod
treatment. A) Removing the mucus layer with NAC after tegaserod treatment lowers the
survival rate. B) Treatment with NAC trends to a slower and less complete recovery
from colitis. (n=6-10 per group)
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There are fewer positive cultures produced from tissue from tegaserod treated DSS mice.
(n=8-9 per group)
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Figure 3
Treatment with the 5-HT4 receptor antagonist, GR113808, trends to increasing visceral
sensitivity in non-inflamed animals compared to tegaserod treated non-inflamed animals.
(n=5-8 per group)
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